Rolled prosthetic valve support

Information

  • Patent Grant
  • 10835377
  • Patent Number
    10,835,377
  • Date Filed
    Friday, May 19, 2017
    6 years ago
  • Date Issued
    Tuesday, November 17, 2020
    3 years ago
Abstract
Apparatus is provided for use at a native valve of a heart of a subject. The apparatus includes a delivery tube, transluminally advanceable to the heart; and a prosthetic valve support, configured to support a prosthetic valve at the native valve, and comprising an upstream support portion. The upstream support portion has a working configuration in which it is generally annular and has (1) a tissue-contacting side configured to be placed against an atrial surface of the native valve, and (2) an opposing side, and defines an opening therebetween. The upstream support portion also has a delivery configuration in which the upstream support portion is rolled up to define a channel, and is disposed within the delivery tube. The upstream support portion is configured to be transitioned from the delivery configuration to the working configuration by being exposed from the delivery tube, and unrolled.
Description
FIELD OF THE INVENTION

Some applications of the present invention relate in general to valve replacement. More specifically, some applications of the present invention relate to prosthetic cardiac valves and techniques for implantation thereof.


BACKGROUND

Ischemic heart disease causes regurgitation of a heart valve by the combination of ischemic dysfunction of the papillary muscles, and the dilatation of the ventricle that is present in ischemic heart disease, with the subsequent displacement of the papillary muscles and the dilatation of the valve annulus.


Dilation of the annulus of the valve prevents the valve leaflets from fully coapting when the valve is closed. Regurgitation of blood from the ventricle into the atrium results in increased total stroke volume and decreased cardiac output, and ultimate weakening of the ventricle secondary to a volume overload and a pressure overload of the atrium.


SUMMARY OF THE INVENTION

For some applications of the invention, a prosthetic valve support is provided for facilitating minimally invasive (e.g., transcatheter and/or transluminal) implantation of a prosthetic valve at a native valve of a subject. The native valve typically has native check valve functionality, i.e., it functions as a check valve. The prosthetic valve support is typically couplable to the native valve (e.g., to leaflets thereof) of the subject without eliminating the check valve functionality of the native valve. The prosthetic valve is subsequently implanted at the native valve by coupling the prosthetic valve to the prosthetic valve support, typically by expanding the prosthetic valve within an opening defined by the prosthetic valve support. The implantation of the prosthetic valve at the native valve replaces, at least in part, the check valve functionality of the native valve with substitute check valve functionality of the prosthetic valve. The prosthetic valve support comprises an upstream support portion, configured to be placed against an upstream surface of the native valve, and shaped to define an opening.


For some applications, the upstream support portion is delivered to the native valve in a delivery configuration (e.g., rolled within a delivery tube), and the tissue-engaging elements comprise tissue anchors that are driven through the upstream support portion and into the annulus of the native valve while at least part of the upstream support portion is still within the delivery tube (e.g., is still in the delivery configuration).


For some applications, the prosthetic valve support comprises tissue-engaging elements, such as clips. For some such applications, the clips comprise two arms, and a fabric which covers the arms, and typically has a greater surface area than the clip arms. The fabric is configured to cushion (e.g., soften and/or disperse) forces applied by the clips on the tissue to which the clip is coupled. The clips of the prosthetic valve support are typically coupled to leaflets of the native valve and are further typically configured to move with the native beating of the leaflets so as not to eliminate the check valve functionality of the native valve.


For some applications, tissue-engaging elements are coupled to the native valve (e.g., to the leaflets thereof) and the upstream support portion is subsequently coupled to the tissue-engaging elements. For such applications, each tissue-engaging element is typically coupled to a longitudinal guide member along (e.g., over) which the upstream support portion is slidable. For some such applications, the tissue-engaging elements comprise clips, configured to be coupled to the leaflets of the native valve. For some such applications, the tissue-engaging elements comprise tissue anchors that are coupled to the annulus.


For some applications in which the tissue-engaging elements comprise tissue anchors, more than one tissue anchor is delivered through one delivery tube. For example, the anchors may each fit snugly through the delivery tube, and be delivered sequentially.


As described hereinabove, a prosthetic valve is typically coupled to the prosthetic valve support after the prosthetic valve support has been coupled to the native valve. For some applications, the prosthetic valve comprises a valve body, and a downstream portion that is configured to inhibit contact between chordae tendineae of the heart and the valve body, such as to prevent damage to the chordae tendineae. Typically, an outer surface of the downstream portion is covered with a fabric. For some applications, the prosthetic valve comprises a valve body that comprises an upstream portion, a downstream portion, and an elastic portion between the upstream portion and the downstream portion. For some such applications, the prosthetic valve is configured to facilitate coupling of a pre-determined portion of the prosthetic valve to the prosthetic valve support (e.g., to the upstream support portion thereof).


There is therefore provided, in accordance with an application of the present invention, apparatus for use with a prosthetic valve at a native valve of a heart of a subject, the apparatus including:


a delivery tube, transluminally advanceable to the heart of the subject;


a prosthetic valve support, configured to support the prosthetic valve at the native valve, and including an upstream support portion, the upstream support portion:

    • having a working configuration in which the upstream support portion is generally annular and has (1) a tissue-contacting side configured to be placed against an atrial surface of the native valve, and (2) an opposing side, and defines an opening therebetween, and
    • having a delivery configuration in which the upstream support portion defines a channel having a central longitudinal axis, and is configured to be disposed within the delivery tube;


a tissue anchor, configured to be disposed within the channel, and slidable through at least part of the channel; and


an anchor driver, slidable within the delivery tube and the channel, and configured to anchor the upstream support portion to tissue of the heart by driving the tissue anchor from the opposing side through the upstream support portion and into the tissue, while at least part of the upstream support portion is disposed within the delivery tube.


In an application, the tissue anchor includes a helical tissue anchor, and is configured to be driven into the tissue by being rotated.


In an application, the upstream support portion is configured to be transitioned from the delivery configuration to the working configuration by being unrolled.


In an application:


in the delivery configuration, the upstream support portion has a distal portion and a proximal portion, and the channel is defined between the distal portion and the proximal portion,


the anchor includes a first anchor, and the anchor driver is configured to anchor the distal portion of the upstream support portion to the tissue by driving the first anchor through the distal portion of the upstream support portion, and


the apparatus is configured such that:

    • the proximal portion of the upstream support portion is configured to be at least partly exposed from the delivery tube subsequently to the anchoring of the distal portion, and the apparatus further includes a second anchor, configured to be driven through the proximal portion of the upstream support portion and into the tissue subsequently to the exposing.


In an application, in the delivery configuration, the upstream support portion has a distal portion and a proximal portion, and shapes the channel to be an uninterrupted lumen between the distal portion and the proximal portion.


In an application, the anchor driver is configured to slide the tissue anchor through at least most of the channel before driving the anchor through the upstream support portion.


In an application, the delivery tube is configured to be transluminally advanced while the upstream support portion is disposed within a distal portion of the delivery tube, and while the tissue anchor and a distal portion of the anchor driver are disposed within the channel.


In an application, the delivery tube is configured to retain the upstream support portion in the delivery configuration, and the upstream support portion is configured to automatically transition toward the working configuration upon becoming exposed from the delivery tube.


In an application, in the delivery configuration, at any given part of the upstream support portion, the opposing side of the upstream support portion is disposed closer to the central longitudinal axis than is the tissue-contacting side.


In an application, while the upstream support portion is in the delivery configuration and disposed within the delivery tube, the channel shares a common central longitudinal axis with the delivery tube, and the anchor driver is configured to drive the tissue anchor through the upstream support portion by moving the tissue anchor along the common central longitudinal axis.


In an application, the delivery tube is configured to facilitate the driving of the tissue anchor through the upstream support portion by deflecting a portion of the prosthetic valve support to intersect with the common central longitudinal axis by pressing the portion of the prosthetic valve support against the tissue.


There is further provided, in accordance with an application of the present invention, a method for anchoring a prosthetic valve support to a native valve of a heart of a subject, the native valve having an annulus and a plurality of leaflets, the prosthetic valve support including an upstream support portion that is configured to be placed against an atrial surface of the annulus, the method including:


transluminally advancing, to the heart of the subject, the upstream support portion, while the upstream support portion (1) is in a delivery configuration thereof in which the upstream support portion has a distal portion and a proximal portion, and defines a channel therebetween, and (2) is disposed within a delivery tube;


advancing, out of a distal end of the delivery tube, the distal portion of the upstream support portion;


using an anchor driver at least a distal end of which is disposed within the channel, anchoring the distal portion of the upstream support portion to a site of the annulus by driving an anchor through the distal portion of the upstream support portion and into the site; and


subsequently, facilitating transition of the upstream support portion into a working configuration in which the upstream support portion is generally annular, and is disposed against the annulus.


In an application, transluminally advancing the upstream support portion includes transluminally advancing the delivery tube while the upstream support portion is disposed within a distal portion of the delivery tube, and while the tissue anchor and a distal portion of the anchor driver are disposed within the channel.


In an application, facilitating transition of the upstream support portion into the working configuration includes facilitating unrolling of the upstream support portion into the working configuration.


In an application, facilitating transition of the upstream support portion into the working configuration includes exposing the upstream support portion from the delivery tube such that the upstream support portion transitions automatically into the working configuration.


In an application, the method further includes advancing the tissue anchor through at least most of the channel prior to anchoring the distal portion.


In an application:


the anchor includes a first anchor, and the site includes a first site, and


the method further includes, subsequently to anchoring the distal portion, sliding the anchor driver proximally within the channel and subsequently anchoring, using a second anchor, a proximal portion of the upstream support portion to a second site of the annulus.


In an application, the method further includes pressing the distal portion against the site such that a plane of the distal portion is disposed at greater than 45 degrees with respect to a longitudinal axis of the delivery tube.


In an application:


while the upstream support portion is in the delivery configuration and disposed within the delivery tube, the channel shares a common central longitudinal axis with the delivery tube, and


driving the anchor through the distal portion includes driving the anchor through the distal wall by moving the tissue anchor along the common central longitudinal axis.


In an application:


the method further includes pressing the distal portion against the site such that the distal portion deflects with respect to a central longitudinal axis of the channel, and driving the tissue anchor through the distal portion includes moving the anchor driver distally within the channel while the distal portion is pressed against the site.


There is further provided, in accordance with an application of the present invention, a method for anchoring a prosthetic valve support to a native valve of a heart of a subject, the native valve having an annulus and a plurality of leaflets, the prosthetic valve support including an upstream support portion that is configured to be placed against an atrial surface of the annulus, the method including:


transluminally advancing, to the heart of the subject, the upstream support portion, while the upstream support portion (1) is in a delivery configuration thereof in which the upstream support portion generally defines a tube that defines a channel, and (2) is disposed within a delivery tube;


advancing, out of a distal end of the delivery tube, a distal portion of the upstream support portion in the delivery configuration thereof;


anchoring the distal portion to a first site of the annulus using an anchor that is reversibly coupled to an anchor driver, by moving the anchor driver distally within the channel of the tube defined by the upstream support portion; and


facilitating unrolling of the upstream support portion into a deployed configuration in which the upstream support portion is generally annular, and is disposed against the annulus.


In an application, the anchor includes a first anchor, and the method further includes anchoring, using a second anchor, a proximal portion of the upstream support portion to a second site of the annulus.


In an application, anchoring the distal portion of the upstream support portion to the first site includes bending the distal portion by pressing the distal portion against the first site, such that moving the anchor driver distally within the channel of the tube defined by the upstream support portion moves the anchor through the distal portion.


In an application, the method further includes pressing the distal portion against the first site such that a plane of the distal portion is disposed at greater than 45 degrees with respect to a longitudinal axis of the delivery tube.


There is further provided, in accordance with an application of the present invention, apparatus for facilitating implantation of an implant at a native valve of a heart of a subject, the apparatus including a tissue-engaging element, the tissue-engaging element including:


a first portion of the apparatus, including:

    • at least one arm, having:
      • a first end, a second end, and a longitudinal axis therebetween, and
      • a face that has a length along the longitudinal axis of the arm, and a width that is orthogonal to the length, the length and the width defining an area of the face, and
    • a fabric, coupled to the arm so as to have a length and a width that define an area of the fabric, the area of the fabric being greater than the area of the face; and


a second portion of the apparatus,


the first end of the arm of the first portion being articulatably coupled to the second portion at a hinge region, and the tissue-engaging element being configured to sandwich tissue in a vicinity of the native valve between the fabric and the second portion of the apparatus.


In an application, the tissue-engaging element is configured to sandwich tissue of the native valve between the fabric and the second portion of the apparatus.


In an application, the area of the fabric is more than twice as great as the area of the face.


In an application, the fabric entirely covers the face.


In an application, the apparatus further includes the implant, and the second portion of the apparatus includes a portion of the implant.


In an application, the fabric is generally shaped to define a saddle shape having a saddle point, the saddle point being disposed in a vicinity of the hinge region.


In an application:


the arm of the first portion includes a first arm, and the face of the first arm includes a first face,


the second portion of the apparatus includes a second arm, having:

    • a first end, a second end, and a longitudinal axis therebetween, and
    • a second face that has a length along the longitudinal axis of the second arm, and a width that is orthogonal to the length of the face of the second arm, the length and the width of second face defining an area of the second face,


the first end of the second arm is articulatably coupled to the first end of the first arm at the hinge region,


the fabric is coupled to the first arm and to the second arm, and is disposed over the first face and the second face, and


the area of the fabric is greater than the sum of the area of the first face and the area of the second face.


In an application, the first face extends laterally from the longitudinal axis of the first arm, the second face extends laterally from the longitudinal axis of the second arm, and the fabric extends further from the longitudinal axis of each of the first and second arms than does the width of the first and second faces, respectively.


In an application, the fabric extends, from the hinge region, further along the longitudinal axis of the first arm than does the first face.


In an application, a portion of the fabric is disposed over a second end of the first arm.


In an application, the portion of the fabric that is disposed over the second end of the first arm defines at least part of a cushion.


In an application, the cushion extends, from the second end of the first arm, away from the second arm.


There is further provided, in accordance with an application of the present invention, apparatus, for implantation at a native valve of a heart of a subject, the native valve including at least a first valve leaflet and a second valve leaflet, each leaflet being coupled to a respective plurality of chordae tendineae, the apparatus including:


a prosthetic valve, including:

    • a tubular valve body, having an upstream end and a downstream end, and configured to be placed between the leaflets of the native valve;
    • at least one valve member, configured to facilitate flow of blood of the subject from the upstream end of the valve body to the downstream end of the valve body, and to inhibit flow of the blood from the downstream end of the valve body to the upstream end of the valve body; and a downstream portion:
    • coupled to the downstream end of the valve body,
    • extending away from the downstream end of the valve body,
    • configured to be placed between the plurality of chordae tendineae coupled to the first valve leaflet, and the plurality of chordae tendineae coupled to the second valve leaflet, and
    • configured to inhibit contact between the chordae tendineae and the valve body.


In an application, the downstream portion includes a frame, and at least an outer surface of the frame is covered with a covering.


In an application, the downstream portion is tubular, and the downstream portion and the valve body define a continuous lumen therethrough.


In an application, the heart of the subject includes a plurality of papillary muscles, and at least part of the downstream portion is configured to be placed in contact with at least one of the papillary muscles.


In an application, the downstream portion includes one or more protrusions, each protrusion extending away from the downstream end of the valve body.


In an application, the valve body has a longitudinal axis therethrough, and includes a circumferential lateral wall that defines a curved plane that circumscribes the longitudinal axis, and the protrusions lie on the plane.


In an application, each protrusion has a transverse cross-sectional shape of an arc, and the arc of each protrusion lies on the curved plane defined by the valve body.


There is further provided, in accordance with an application of the present invention, apparatus, for implantation at a native valve of a heart of a subject, the native valve being disposed between an atrium and a ventricle of the heart, the apparatus including:


a tubular valve body:

    • having an upstream portion, configured to be disposed in the atrium of the heart of the subject,
    • having a downstream portion, configured to be disposed in the ventricle of the subject,
    • having an elastic portion, disposed between the upstream portion and the downstream portion, and elastically coupling the upstream portion to the downstream portion, and
    • shaped to define a continuous lumen through the upstream portion, the elastic portion, and the downstream portion; and


at least one valve member, disposed in the lumen of the valve body, and configured to facilitate flow of blood of the subject from the upstream portion of the valve body to the downstream portion of the valve body, and to inhibit flow of the blood from the downstream portion of the valve body to the upstream portion of the valve body.


In an application, the at least one valve member is coupled to the downstream portion of the valve body.


In an application, the native valve includes a plurality of native leaflets, and the downstream portion of the valve body is configured to be coupled to the native leaflets.


In an application, the apparatus further includes a plurality of clips, configured to facilitate the coupling of the downstream portion of the valve body to the native leaflets.


In an application, each clip:


includes at least two clip arms, articulatably coupled to each other, and


is reversibly closeable.


In an application, the clips are coupled to the downstream portion of the valve body, and the downstream portion of the valve body is configured to be coupled to the native leaflets by the clips being coupled to the native leaflets.


In an application, each clip of the plurality of clips is articulatably coupled to the downstream portion of the valve body.


In an application, the native valve includes an annulus having an upstream surface, and the apparatus further includes a prosthetic valve support:


including (1) an upstream support portion, configured to be placed against the upstream surface of the annulus of the native valve, and (2) the plurality of clips, coupled to the upstream support portion, and


shaped to define an opening therethrough that is configured to receive the prosthetic valve,


and the clips are configured to facilitate the coupling of the downstream portion of the valve body to the native leaflets by coupling the prosthetic valve support to the native leaflets.


There is further provided, in accordance with an application of the present invention, apparatus for facilitating implantation of a prosthetic valve at a native valve of a heart of a subject, the native valve having a plurality of native leaflets, the apparatus including:


at least one tissue-engaging element, configured to be transluminally delivered to the native valve, and to be coupled to a native leaflet of the subject;


an upstream support portion, configured to be transluminally delivered to the native valve, and to be intracorporeally coupled to the tissue-engaging element;


at least one locking element, configured to intracorporeally couple the tissue-engaging element to the upstream support portion such that the tissue-engaging element is movable with respect to the upstream support portion.


In an application, the tissue-engaging element includes a clip, having at least a first arm and a second arm, the first and second arms being articulatably coupled to each other, and the clip is reversibly openable and closeable.


In an application:


the first arm has a first face and the second arm has a second face,


the tissue-engaging element includes a fabric that is coupled to the first arm and to the second arm, and is disposed over the first face and the second face, and


the fabric defines an area that is greater than the sum of the area of the first face and the area of the second face.


In an application, the apparatus further includes a clip controller, configured to interface with the clip, and to facilitate the reversible opening and closing of the clip.


In an application, the apparatus further includes at least one flexible longitudinal guide member, and the apparatus is configured such that, when the locking element couples the tissue-engaging element to the upstream support portion, at least a portion of the flexible longitudinal guide member is disposed between the tissue-engaging element and the upstream support portion.


In an application:


the flexible longitudinal guide member is coupled to the locking element and to the tissue-engaging element,


the locking element is configured to couple the tissue-engaging element to the upstream support portion by the locking element being coupled to the upstream support portion, and


flexibility of the at least the portion of the flexible longitudinal guide member facilitates the coupling of the tissue-engaging element to the upstream support portion such that the tissue-engaging element is movable with respect to the upstream support portion.


There is further provided, in accordance with an application of the present invention, a method for anchoring a prosthetic valve support to a native valve of a subject, the native valve having an annulus and a plurality of leaflets, the method including:


transluminally advancing a delivery tube such that a distal end of the delivery tube is disposed in a vicinity of a first site of the annulus;


advancing a first anchor distally through the delivery tube by advancing an anchor driver through the delivery tube, the anchor driver having a distal end to which the first anchor is reversibly coupled, and the first anchor being coupled to a distal end of a first guide member;


anchoring the first anchor to tissue of the first site of the annulus using the anchor driver;


subsequently, decoupling the anchor driver from the first anchor, and proximally withdrawing the anchor driver such that at least a portion of the first guide member remains disposed within the delivery tube, and such that the distal end of the first guide member remains coupled to the first anchor;


subsequently, advancing a second anchor through the delivery tube such that the second anchor passes at least the portion of the first guide member, the second anchor being coupled to a distal end of a second guide member;


positioning the distal end of the delivery tube in a vicinity of a second site of the annulus; and


anchoring the second anchor to tissue of the second site of the annulus;


sliding the prosthetic valve support distally over the first guide member and the second guide member; and


anchoring the prosthetic valve support to the native valve by inhibiting further sliding of the prosthetic valve support with respect to the first guide member and the second guide member.


In an application:


transluminally advancing the delivery tube includes transluminally advancing a delivery tube through which the first anchor fits snugly and through which the second anchor fits snugly,


advancing the first anchor distally through the delivery tube includes advancing the first anchor distally through the delivery tube in which the first anchor fits snugly, and


advancing the second anchor distally through the delivery tube includes advancing the second anchor distally through the delivery tube in which the second anchor fits snugly.


In an application, advancing the anchor driver through the delivery tube includes advancing the anchor driver through a delivery tube through which the anchor driver fits snugly.


In an application, advancing anchor driver includes advancing an anchor driver that has a transverse cross-sectional area that is more than twice as great as a transverse cross-sectional area of the first guide member.


In an application, anchoring the first anchor, anchoring the second anchor, and anchoring the prosthetic valve support include anchoring the first anchor, anchoring the second anchor, and anchoring the prosthetic valve support without eliminating movement of the leaflets of the native valve.


In an application, anchoring the first anchor, anchoring the second anchor, and anchoring the prosthetic valve support include anchoring the first anchor, anchoring the second anchor, and anchoring the prosthetic valve support without engaging the leaflets of the native valve.


In an application, anchoring the first anchor at the first site of the annulus includes anchoring the first anchor at a first site of the annulus that is in the vicinity of a first commissure of the native valve, and anchoring the second anchor at the second site of the annulus includes anchoring the second anchor at a second site of the annulus that is in the vicinity of a second commissure of the native valve.


In an application, the method further includes advancing a guidewire to the first commissure of the native valve, the delivery tube being shaped to define a lateral opening through which the guidewire is slidable, and transluminally advancing the delivery tube to the first site of the annulus includes sliding the delivery tube over the guidewire.


In an application, transluminally advancing the delivery tube to the first site that is in the vicinity of the first commissure includes transluminally advancing the delivery tube to a first site that is a distance from the first commissure, the distance of the first site from the first commissure being at least in part dependent on a distance between the distal end of the delivery tube and the lateral opening of the delivery tube.


The present invention will be more fully understood from the following detailed description of applications thereof, taken together with the drawings, in which:





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A-C and 2 are schematic illustrations of a system comprising an implant comprising one or more tissue-engaging elements, in accordance with some applications of the invention;



FIGS. 3A-B and 4A-B are schematic illustrations of a prosthetic valve that comprises a tubular valve body and a downstream portion, in accordance with some applications of the invention;



FIGS. 5A-D are schematic illustrations of a system comprising an upstream support portion, a plurality of tissue-engaging elements, a locking element, and a prosthetic valve, in accordance with some applications of the invention;



FIGS. 6 and 7A-B are schematic illustrations of a prosthetic valve having a tubular valve body that comprises an upstream portion, a downstream portion, and an elastic portion disposed between the upstream portion and the downstream portion, in accordance with some applications of the invention;



FIGS. 8-10 are schematic illustrations of a system for delivering and anchoring to a native valve, a prosthetic valve support comprising an upstream support portion, in accordance with some applications of the invention; and



FIGS. 11A-C are schematic illustrations of a system for delivering and anchoring to a native valve, a prosthetic valve support comprising an upstream support portion, in accordance with some applications of the invention.





DETAILED DESCRIPTION OF EMBODIMENTS

Reference is made to FIGS. 1A-C and 2, which are schematic illustrations of a system 20 comprising an implant 22, and apparatus for facilitating implantation of the implant at a native heart valve 10 of a subject, the apparatus comprising a tissue-engaging element 24, in accordance with some applications of the invention. FIG. 1A shows system 20 comprising a system 20a, and tissue-engaging element 24 comprising a tissue-engaging element 24a, in accordance with some applications of the invention. FIG. 1B shows system 20 comprising a system 20b, and tissue-engaging element 24 comprising a tissue-engaging element 24b, in accordance with some applications of the invention. FIG. 1C shows system 20 comprising a system 20c, and tissue-engaging element 24 comprising a tissue-engaging element 24c, in accordance with some applications of the invention. FIG. 2 shows system 20b having been implanted at native valve 10, in accordance with some applications of the invention.


Tissue-engaging element 24 (e.g., tissue-engaging elements 24a, 24b, and 24c) comprises at least one arm 26. Typically, element 24 comprises two arms 26 (e.g., a first arm 26x and a second arm 26y), which are articulatably coupled to each other at a hinge region 34. Each arm 26 has a length from a first end 28 thereof at hinge region 34, to a second end 30 thereof, and a longitudinal axis therebetween. Each arm 26 also has a face 32, which has a length along the longitudinal axis of the arm, a width that is orthogonal to the length, and an area defined by the width and the length.


Tissue-engaging element 24 is configured to sandwich tissue in the vicinity of the native heart valve using the at least one arm 26. Typically, element 24 is configured to sandwich the tissue between first arm 26x and second arm 26y. Alternatively, element 24 may comprise only one arm (e.g., arm 26x), coupled to another portion of the apparatus (e.g., a portion of implant 22), and may be configured to sandwich the tissue between arm 26x and the other portion of the apparatus. Typically, and as shown in FIG. 2, element 24 is configured to sandwich, between arms 26, tissue of the native heart valve, such as tissue of a native leaflet 12 of the native heart valve.


Tissue-engaging element 24 further comprises a fabric 40, coupled to arm 26 so as to have a length and a width that define an area of the fabric (e.g., an area of the fabric that is disposed over face 32). Typically, the area of fabric 40 is greater than the area of face 32, such that part of the fabric is disposed over face 32, and part of the fabric extends past the face. For example, FIGS. 1A and 1B show fabric 40 of tissue-engaging elements 24a and 24b, respectively, extending laterally (i.e., width-ways) from face 32 (that is, the width of the fabric is greater than the width of the face, and the fabric extends further from the longitudinal axis of the arm, than does the face). Similarly, FIGS. 1B and 1C show fabric 40 of tissue-engaging elements 24b and 24c, respectively, extending away from second end 30 of arm 26x (that is, the length of fabric 40 is greater than the length of face 32, and the fabric extends further along the longitudinal axis of the arm from the hinge, than does the face). Fabric 40 is configured to cushion (e.g., soften and/or disperse) forces applied by element 24 on the tissue to which element 24 is coupled.


It is to be noted that throughout this patent application, including the specification and the claims, the term “fabric” typically means a woven fabric, but may also include other sheet-like materials, such as sheets of polymer and/or silicone.


For some applications, the area of fabric 40 is more than twice as great as the area of face 32. For some applications, the fabric entirely covers face 32. Alternatively, fabric 40 may be shaped to define a hole 42 through which a portion of arm 26 (e.g., a portion of face 32 thereof) may contact the tissue being sandwiched (e.g., the tissue of the native leaflet). For example, and as shown in FIGS. 1A-C, arm 26y may be shaped to define one or more barbs 44, configured to protrude through hole 42, and pierce the tissue being sandwiched, so as to facilitate gripping of the tissue.


Typically, tissue-engaging elements 24 comprise two arms 26 (e.g., arms 26x and 26y) and two respective faces 32, and fabric 40 spans both faces, and is bent (e.g., folded) to define a trough 48 in the vicinity of hinge region 34, thereby forming a clip with two tissue-engaging surfaces comprising fabric 40, and corners 50 that define respective ends of the trough. Typically, the area of fabric 40 is greater than (e.g., more than twice as great as) the sum of the respective areas of both faces 32, and thereby at least part (e.g., more than half) of fabric 40 is not directly backed by an arm (e.g., a face thereof), thereby providing flexibility to the clip. For some applications, and as shown in FIGS. 1A-B for tissue-engaging elements 24a and 24b, fabric 40 is shaped, and coupled to arms 26, so as to define a saddle shape. A saddle point 46 of the saddle shape is typically disposed in the vicinity of hinge region 34 (e.g., at hinge region 34), such that “wings” 49 of the fabric protrude laterally (i.e., width-ways) from faces 32, and trough 48 curves downward toward corners 50.


As shown in the magnified area of FIG. 2, wings 49 of fabric 40 that protrude laterally from arms 26 engage the tissue being sandwiched (e.g., leaflets 12), and provide lateral flexible coupling regions 82 that cushion (e.g., soften and/or disperse) forces applied by tissue-engaging element 24 on leaflet 12. Typically, and as shown in the magnified area of FIG. 2, element 24 is coupled to leaflet 12 such that, for at least some chordae tendineae 86 that are coupled to the leaflet being sandwiched, the respective points at which the chordae tendineae are coupled to the leaflet are disposed within trough 48 of fabric 40, and the chordae tendineae extend out of corners 50, and toward the papillary muscle 14 to which they are coupled.


Typically, and as shown in FIGS. 1A-C, fabric 40 is disposed over second end 30 of at least arm 26x. For some applications, and as shown in FIGS. 1B-C, fabric 40 is shaped to define a cushion 52 in the vicinity of second end 30 of arm 26x. For some applications, cushion 52 comprises a soft material (e.g., enveloped by fabric 40). For some applications, and as shown in FIGS. 1B-C, cushion 52 extends from second end 30 of arm 26x, away from arm 26y. Cushion 52 is configured to cushion (e.g., soften and/or disperse) forces applied by element 24 on the tissue to which element 24 is coupled. As shown in FIG. 2, cushion 52 provides a cushioning region 84 that cushions (e.g., softens and/or disperses) forces applied by tissue-engaging element 24 on leaflet 12.


For some applications, and as shown in FIGS. 1A-C, implant 22 comprises a prosthetic valve support 60, comprising an upstream support portion 62, configured to be placed against an upstream surface of an annulus of the native valve, e.g., as shown in FIGS. 2A-B, and shaped to define an opening 64 that is configured to receive a prosthetic valve. For some applications, prosthetic valve support 60 comprises a stabilizing member 154, described in more detail hereinbelow with reference to FIGS. 5A-D, typically coupled to elements 24. For some applications, implant 22 comprises a prosthetic valve.


For some applications, tissue-engaging elements 24 are articulatably coupled to upstream support portion 62 such that, when prosthetic valve support 60 is coupled to the native valve, native movement (e.g., beating) of the leaflets of native valve 10 is not eliminated, and thereby check-valve functionality of the native valve is not eliminated. For some such applications, prosthetic valve support is thereby implantable without the use of cardiopulmonary bypass.


Reference is made to FIGS. 3A-B and 4A-B, which are schematic illustrations of apparatus 100 comprising a prosthetic valve 102 that comprises a tubular valve body 104 and a downstream portion 106, in accordance with some applications of the invention. Prosthetic valve 102 comprises at least one valve member, such as a prosthetic leaflet (not shown). Body 104 has an upstream end 108 and a downstream end 110, and downstream portion 106 is coupled to downstream end 110. Downstream portion 106 extends away (i.e., downstream) from downstream end 110, and is configured to inhibit contact between the chordae tendineae and valve body 104.


Typically, valve body 104 comprises a frame 112, such as a stent-like wire frame. For some applications, and as shown in FIGS. 3A-B, downstream portion 106 also comprises a frame. For some applications, frame 112 is shaped to define downstream portion 106 (e.g., body 104 and downstream portion 106 comprises respective portions of frame 112).


Typically, apparatus 100 (e.g., prosthetic valve 102 thereof) comprises a covering 114, disposed over (e.g., covering) an inner surface of frame 112. Typically, covering 114 is also disposed over an inner surface of downstream portion 106. Further typically, covering 114 is also disposed over an outer surface of portion 106 (e.g., extends around a distal end of apparatus 100). Sections A-A of FIG. 3A and FIG. 3B show such placements of covering 114.



FIG. 3A shows downstream portion 106 comprising a tubular downstream portion 106a, which is coupled to the downstream end of valve body 104 such that the downstream portion and the valve body define a continuous lumen therethrough. FIG. 3B shows downstream portion 106 a downstream portion 106b that comprises one or more (e.g., two) protrusions 116, each of which protrudes away from the valve body. Typically, protrusions 116 lie on a curved plane defined by valve body 104 (e.g., by a circumferential lateral wall of the valve body, such as that defined by frame 112), e.g., protruding downstream away from the valve body. For some applications, each protrusion 116 has a transverse cross-sectional shape of an arc, and the arc of each protrusion lies on the curved plane defined by valve body 104. For example, downstream portion 106b may resemble tubular downstream portion 106a having had portions thereof cut away.


As described hereinabove, downstream portion 106 is configured to inhibit contact between chordae tendineae 86 and valve body 104. As shown in FIG. 4B, for some applications, when apparatus 100 is implanted at the native valve, portion 106 (e.g., protrusions 116 thereof) is in contact with at least one (e.g., two) papillary muscles 14. For some such applications, portion 106 is configured to move the papillary muscles away from each other, and thereby to move at least portions of chordae tendineae 86 away from valve body 104. Covering 114 on the outer surface of portion 106 protects the chordae tendineae and/or papillary muscles from portion 106 (e.g., metallic components of the frame thereof). It is hypothesized that, for some applications, such inhibition of contact between the chordae tendineae and the valve body reduces a likelihood of damage to the chordae tendineae and/or improves blood flow through prosthetic valve 102.


Reference is made to FIGS. 5A-D, which are schematic illustrations of a system 140 comprising an upstream support portion 142, a plurality of tissue-engaging elements 144, a locking element 146, and a prosthetic valve 148, in accordance with some applications of the invention. System 140 is configured such that upstream support portion 142 is couplable to tissue-engaging elements 144 (1) intracorporeally, (2) subsequent to coupling of the tissue-engaging elements to tissue of native valve 10, and (3) prior to coupling of prosthetic valve 148 to the upstream support portion. For some applications of the invention, upstream support portion 142 and tissue-engaging elements 144, when coupled to each other, act as a prosthetic valve support 150.



FIG. 5A shows two tissue-engaging elements 144 being coupled to respective leaflets 12 of native valve 10. For some applications, and as shown in FIGS. 5A-D, elements 144 comprise clips that are reversibly openable and closeable, and comprise a clip controller interface that facilitates the reversible opening and closing by interfacing (e.g., reversibly interfacing) with a clip controller 152. For some applications, tissue-engaging elements 144 are delivered within a delivery tube 145. Typically, system 140 (e.g., prosthetic valve support 150 thereof) further comprises a stabilizing member 154, such as a stabilizing band, coupled to tissue-engaging elements 144, and configured to form a ring that is shaped to define an opening 155 therethrough (shown in FIGS. 1A-C for stabilizing member 154 of system 20).


As shown in FIGS. 5A-B, tissue-engaging elements 144 are typically able to move toward and away from each other, following coupling thereof to leaflets 12. It is hypothesized that such movement allows the leaflets of the native valve to continue to move, and therefore facilitates coupling of the tissue-engaging elements to the native valve (e.g., to the leaflets thereof) without eliminating the native valve function. As also shown in FIGS. 5A-B, stabilizing member 154 is typically flexible, so as to facilitate such movement of tissue-engaging elements 144. For example, when the tissue-engaging elements are disposed away from each other (e.g., when leaflets 12 are open; FIG. 5B), member 154 may form the ring that is shaped to define the opening therethrough, and when the tissue-engaging elements are disposed close to each other (e.g., when leaflets 12 are closed; FIG. 5A, mutatis mutandis), member 154 may form a general lemniscate.



FIGS. 5B-C show, subsequent to the coupling of tissue-engaging elements 144 to leaflets 12, upstream support portion 142 being delivered to the upstream (e.g., atrial) surface of the annulus of native valve 10, and coupled to the tissue-engaging elements. Upstream support portion 142 is typically delivered in a compressed (e.g., crimped) configuration within a delivery tube 156. FIG. 5B shows upstream support portion 142 being deployed out of delivery tube 156 and expanding (e.g., automatically expanding) toward an expanded configuration thereof. For some applications, delivery tube 156 comprises delivery tube 155. That is, for some applications, upstream support portion 142 is delivered within and/or via the same delivery tube as are tissue-engaging elements 144.


Typically, locking element 146 comprises a ratcheting element 158, comprising a plurality of ratchet teeth 160. Further typically, system 140 (e.g., prosthetic valve support 150 thereof) comprises a plurality of longitudinal guide members 162, each longitudinal guide member coupled to a respective tissue-engaging element, and each locking element 146 (e.g., ratcheting element 158) is coupled to and/or defined by a respective longitudinal guide member. Upstream support portion 142 is slidable along longitudinal guide members 162 (e.g., each longitudinal guide member is slidable through a respective hole 164 defined by the upstream support portion), typically by being pushed along the longitudinal guide members by one or more pushers 168 that are themselves typically slidable over the longitudinal guide members. Such sliding is typically facilitated by providing a counter force by simultaneous pulling on longitudinal guide members 162.


As shown in FIG. 5C, upstream support portion 142 typically comprises a plurality of receiving elements 166, disposed at a respective hole 164, and configured (1) to allow slidable passage of a respective longitudinal guide member 162 through the respective hole, and (2) to couple (e.g., lock) to a respective locking element 146. For example, each receiving element may comprise an eyelet, disposed around a respective hole, and configured to facilitate one-way movement therethrough of ratcheting element 158.


Coupling of upstream support portion 142 to tissue-engaging elements 144 thereby forms prosthetic valve support 150. Typically, tissue-engaging elements 144 are flexibly coupled to upstream support portion 142 (i.e., can move with respect to the upstream support portion while coupled to the upstream support portion). For example, longitudinal guide members 162 are typically flexible, and a portion of each flexible longitudinal guide member is disposed between a respective tissue-engaging element 144 (i.e., the point at which the longitudinal guide member is coupled to the tissue-engaging element) and upstream support portion 142 (i.e., the point at which the longitudinal guide member is coupled to the upstream support portion). Such coupling typically configures prosthetic valve support 150 to be couplable to native valve 10 without eliminating the valve function thereof, e.g., as described hereinabove. Upstream support portion 142 is typically annular, and shaped to define an opening therethrough, through which blood may flow.


Typically, a proximal portion of each longitudinal guide member 162 is decoupled from a distal portion of that longitudinal guide member and/or from the respective locking element 146, such as, but not limited to, by cutting. Such decoupling may be performed before introduction of prosthetic valve 148, as shown, or subsequently thereto.


Subsequently to coupling of upstream support portion 142 to tissue-engaging elements 144 (and thereby formation of prosthetic valve support 150), prosthetic valve 148 is delivered to native valve 10 and coupled to the tissue-engaging elements (e.g., to the prosthetic valve support) (FIG. 5D). Typically, prosthetic valve 148 comprises an expandable prosthetic valve, and is deployed (e.g., from a delivery tube 149) such that it (1) expands within the opening defined by upstream support portion 142 and/or the opening defined by stabilizing member 154, (2) applies a radially-expansive force against the upstream support portion and/or the stabilizing member, and (3) thereby becomes coupled thereto. For clarity, prosthetic valve 148 is shown in phantom outline.


Reference is made to FIGS. 6 and 7A-B, which are schematic illustrations of a prosthetic valve 180 having a tubular valve body 182 that comprises an upstream portion 184, a downstream portion 186, and an elastic portion 188 disposed between the upstream portion and the downstream portion, in accordance with some applications of the invention. Prosthetic valve 180 is shaped to define a continuous lumen through portions 184, 188, and 186. Prosthetic valve 180 is configured to be implanted at native valve 10 such that an upstream portion 184 is disposed in an atrium 6 of the heart of the subject, and such that downstream portion 186 is disposed in a ventricle 8 of the heart of the subject. For example, prosthetic valve 180 may be coupled to a prosthetic valve support 190 that has previously coupled to the native valve. Prosthetic valve support 190 typically comprises tissue-engaging elements 144, upstream support portion 142, and stabilizing member 154, described hereinabove. For some applications, prosthetic valve support 190 comprises prosthetic valve support 150, described hereinabove. For some applications, prosthetic valve support 190 comprises a prosthetic valve support that comprises tissue-engaging elements 144, upstream support portion 142, and stabilizing member 156 that are provided pre-coupled to each other. For some applications, prosthetic valve support 190 may comprise another prosthetic valve support.


Tubular valve body 182 typically comprises a frame 192, such as a stent-like wire frame. As shown in FIG. 6, prosthetic valve 180 typically further comprises a covering 194, disposed over (e.g., covering) an inner surface of frame 192, thereby providing a sealed lumen from an upstream end to a downstream end of the tubular valve body. Typically, an excess of covering 194 is provided in the vicinity of elastic portion 188, so as to facilitate elastic stretching of the elastic portion.


Typically, prosthetic valve 180 comprises an expandable prosthetic valve, and is deployed such that it (1) expands within the opening defined by upstream support portion 142 and/or the opening defined by stabilizing member 154, (2) applies a radially-expansive force against the upstream support portion and/or the stabilizing member, and (3) thereby becomes coupled thereto. Typically, and as shown in FIGS. 7A-B, downstream portion 186 is expanded and coupled to stabilizing member 154 before upstream portion 184 is expanded and coupled to upstream support portion 142. While downstream portion 186 is coupled to member 154, and before upstream portion 184 is coupled to portion 142, elastic portion 188 may be stretched and compressed e.g., such as by moving upstream portion 184 further upstream and downstream. Such stretching and compressing changes a length of prosthetic valve 180, and for some applications, facilitates the coupling of a pre-determined portion of the prosthetic valve (e.g., of upstream portion 184) to upstream support portion 142, irrespective, to some degree, of (a) a distance between tissue-engaging elements 144 and upstream support portion 142, and/or (b) a dimension of native valve 10 (e.g., a length of leaflets 12). For some applications, such stretching and compressing adjusts a degree of tension of elastic portion 188, and may alternatively or additionally facilitate “tightening” of leaflets 12 against the implanted apparatus, such as drawing of the leaflets toward upstream support portion 142.


Reference is made to FIGS. 8-10, which are schematic illustrations of a system 200 for delivering and anchoring, to native valve 10, a prosthetic valve support 202 comprising an upstream support portion 204, in accordance with some applications of the invention. For some applications of the invention, prosthetic valve support 202 (and/or upstream support portion 204 thereof) comprises another prosthetic valve support described herein (and/or the upstream support portion thereof), such as prosthetic valve support 60 (and/or upstream support portion 62) or prosthetic valve support 150 (and/or upstream support portion 142).


Reference is now made to FIG. 8. System 200 comprises a delivery tube 206, which is shaped to define a lumen therethrough. A guidewire 208 protrudes from a lateral wall of delivery tube 206, such as from a hole 210 in the lateral wall. For some applications, tube 206 is shaped to define a secondary lumen that ends at hole 210, so as to provide guidewire 208 with a dedicated lumen. Guidewire 208 is advanced between leaflets 12 of native valve 10, such that the guidewire is disposed at a join of the leaflets, i.e., at a commissure 16 of the native valve (state A). Guidewire 208 is at least partly stiff, and provides resistance, which facilitates positioning of a distal end of tube 206. For example, guidewire 208 may bias the distal end to be disposed at a site in an arc around the commissure, the arc including part of the annulus and/or being in a vicinity of a fibrous trigone 17. For some applications, guidewire 208 is advanced between leaflets 12 and tube 206 is subsequently slid along (e.g., over) the guidewire. For some applications, tube 206 is advanced with guidewire 208.


A tissue anchor 220 (e.g., a first tissue anchor 220a) is advanced through at least a distal portion of tube 206, and is anchored to tissue of the native valve, such as tissue of the annulus of the native valve (state A). Typically, anchor 220 is advanced using an elongate anchor driver 222. For some applications, anchor 220 comprises a helical anchor, and is anchored to the tissue by being rotated using anchor driver 222.


Anchor driver 222 is reversibly coupled to anchor 220a, and is subsequently decoupled from the anchor and withdrawn proximally (e.g., withdrawn from the body of the subject) (state B). Anchor 220a is coupled to a longitudinal guide member 224 (e.g., a first guide member 224a), which is exposed from a lumen of anchor driver 222 when the driver is withdrawn (i.e., is slid proximally off of member 224). It is to be noted that at least a portion of guide member 224a remains disposed within tube 206. Tube 206 is moved toward a second commissure 14 of valve 10, and positioning of the tube is typically facilitated by guidewire 208 being disposed between leaflets 12 at the commissure, as described hereinabove.


A tissue anchor 220 (e.g., a second tissue anchor 220b) is advanced through at least a distal portion of tube 206, and is anchored to tissue of the native valve, such as tissue of the annulus of the native valve (state B). Typically, anchor 220b is advanced using an elongate anchor driver, such as the same anchor driver 222, or a second anchor driver. It is to be noted that anchor 220 and anchor driver 222 are advanced through tube 206 while at least a portion of first guide member 224a is disposed within tube 206 (i.e., advanced past at least a portion of member 224a).


Anchor driver 222 is subsequently decoupled from anchor 220b and is withdrawn proximally (e.g., withdrawn from the body of the subject) (state C). Anchor 220b is coupled to a longitudinal guide member 224 (e.g., a second guide member 224b), which is exposed from the lumen of anchor driver 222 when the driver is withdrawn. Native valve is thereby left with respective distal ends of two guide members 224 coupled thereto (e.g., coupled to the annulus thereof)(state D).


Reference is now made to FIG. 9. Prosthetic valve support 202 (e.g., upstream support portion 204 thereof) is advanced along (e.g., slid over) guide members 224 (e.g., guide members 224a and 224b) (state A). Typically, support 202 is advanced through delivery tube 206 in a compressed configuration (e.g., a generally cylindrical configuration), and automatically expands into an expanded configuration (e.g., a generally annular configuration) when deployed from the distal end of tube 206. Typically, support 202 is pushed through delivery tube 206 and against the upstream (e.g., atrial) surface of valve 10 using one or more control tubes 226 (e.g., a first control tube 226a and a second control tube 226b). Prosthetic valve support 202 (e.g., upstream support portion 204 thereof) is shaped to define one or more (e.g., two) holes, through which a respective guide member 224 is slidable. Control tubes 226 are shaped to define a lumen through which a respective guide member 224 is slidable, and typically have a transverse width (e.g., a diameter) that is greater than a diameter of the holes in prosthetic valve support 202. Thereby when control tubes 226 are slid distally over guide members 224, they push prosthetic valve support 202 distally (states A and B).


Subsequently, prosthetic valve support 202 is anchored to native valve 10 by inhibiting movement of the prosthetic valve support with respect to guide members 224. For example, a stopper 228 may be slid along each guide member and fastened to the guide member in the vicinity of the prosthetic valve support. For some applications, each guide member 224 comprises two discrete filaments, each filament being slidable through a separate hole in the prosthetic valve support, and the prosthetic valve support is anchored by tying the filaments together, optionally facilitated by a pledget (not shown). Typically, a proximal portion of each guide member is subsequently removed, such as by decoupling that portion from a distal portion, e.g., by cutting.


Reference is now made to FIG. 10. Subsequently, a prosthetic valve 230 is implanted at native valve 10 by being deployed at, and coupled to, prosthetic valve support 202, e.g., as described hereinabove for prosthetic valve 148 with reference to FIG. 5D, mutatis mutandis. For some applications, prosthetic valve 230 comprises tissue-engaging elements 232, such as anchors and/or clips, which facilitate implantation of the prosthetic valve by coupling to leaflets 12 of valve 10. For some such applications, and as shown with reference to FIG. 10, prosthetic valve 148 is partially deployed (state A), and then withdrawn proximally before being fully deployed (state B), so as to sandwich leaflets 12 against prosthetic valve support 202 (e.g., upstream support portion 204 thereof).


Reference is again made to FIGS. 8-10. Typically, each anchor 220 fits snugly through delivery tube 206. Typically, first guide member 224a is sufficiently thin to allow second anchor 220b to snugly fit through the delivery tube and past member 224a. For some applications, anchor driver 222 also fits snugly through delivery tube 206 and/or past member 224a. For example, guide member 224a may have a transverse cross-sectional area that is less than half (e.g., less than 25%, such as less than 10%) of a cross-sectional area of anchor 200 and/or anchor driver 222. For some applications, prosthetic valve support 202 (e.g., upstream support portion 204 thereof), in the compressed configuration thereof, fits snugly through delivery tube 206 and/or past guide members 224. For some applications, prosthetic valve 230, in a compressed configuration thereof, fits snugly through delivery tube 206.


For some applications, anchor 200, prosthetic valve support 202 in the compressed configuration thereof, and prosthetic valve 230 in the compressed configuration thereof, have respective transverse cross-sectional areas that are generally the same as each other (e.g., having a difference of less than 50%, such as less than 30%, such as less than 10%). For example, prosthetic valve support in the compressed configuration is typically less than 50% (e.g., less than 30%, such as less than 10%) wider than each anchor 200. For some such applications, this provides an efficient use of space within delivery tube 206, and thereby allows the use of a narrow delivery tube, e.g., because none of the anchor, support, or valve are more than 50% wider than another. In contrast, for some applications in which two or more anchors and/or anchor drivers are delivered in parallel, a delivery tube would have to be significantly wider than (e.g., twice as wide as) the delivery tube of system 200.


Reference is made to FIGS. 11A-C, which are schematic illustrations of a system 250 for delivering and anchoring to native valve 10, a prosthetic valve support 252 comprising an upstream support portion 254, in accordance with some applications of the invention. Prosthetic valve support 252 is delivered, via a delivery tube 256, to native valve 10 in a delivery configuration in which the prosthetic valve support (e.g., upstream support portion 254 thereof) assumes a shape that generally defines a channel (e.g., a lumen) therethrough, such as a generally tubular (e.g., cylindrical) shape. For example, upstream support portion 254 typically has expanded working configuration in which it is generally annular (FIG. 11A state D), and is “rolled” into the delivery configuration (e.g., into a generally tubular shape).



FIGS. 11B-C show upstream support portion 254 in the delivery configuration thereof, in accordance with respective applications of the invention. In both FIG. 11B and FIG. 11C, state A shows the upstream support portion in the annular expanded configuration, and state B shows the upstream support portion in the tubular delivery configuration. FIG. 11B shows an application in which upstream support portion 254 comprises an upstream support portion 254′ which, in the annular expanded configuration thereof, has an outer diameter d1′ and an inner diameter d2′. FIG. 11C shows an application in which upstream support portion 254 comprises an upstream support portion 254″ which, in the annular expanded configuration thereof, has an outer diameter d1″ and an inner diameter d2″. Upstream support portions 254′ and 254″ are typically identical except that inner diameter d2′ is smaller with respect to outer diameter d1′, than is inner diameter d2″ with respect to outer diameter d1″, and therefore upstream support portion 254′ has a greater surface area than does upstream support portion 254″.


State B of FIGS. 11B-C show upstream support portions 254′ and 254″ in their respective delivery configurations. Upstream support portion 254′ defines a generally continuous tubular shape having a distal end 260, a proximal end 262, and a generally continuous, uninterrupted channel 255′ therebetween along a central longitudinal axis 258 defined by the upstream support portion. Due to its greater relative inner diameter, upstream support portion 254″ defines a tubular shape in which a channel 255″ between distal end 260 and proximal end 262 is interrupted and/or incomplete. FIG. 11C shows an example in which upstream support portion 254″ defines a distal tubular region 261, a proximal tubular region 263, and at least one interruption 265 therebetween. That is, at at least one part of the upstream support portion, compared to an uninterrupted tube, at least one portion of the lateral wall of the tube is absent. Nevertheless, upstream support portion 254″, in the delivery configuration thereof, also defines a channel 255″ therethrough.


The upstream support portion configurations in FIGS. 11B and 11C are intended to illustrate different applications in which the upstream support portion, in the delivery configuration thereof, defines a channel. These figures are not intended to limit the scope of the invention to these particular applications. For example, the scope of the invention includes, inter alia, as shown in state C of FIG. 11B, a delivery configuration in which only opposing edges of the upstream support portion touch, such that few, if any, portions of the lateral wall of the tubular shape completely circumscribe a given longitudinal site of the tubular shape. Nevertheless, the upstream support portion, in this delivery configuration, also defines a channel therethrough.


Upstream support portion 254 has a tissue-contacting side 274, configured to be placed against the atrial surface of valve 10 (e.g., against the annulus of the valve), and an opposing side 276, and defines an opening 278 therebetween. It is to be noted that, in the delivery configuration, opposing side 276 is disposed closer to central longitudinal axis 258 than is tissue-contacting side 274.


Reference is again made to FIG. 11A. Distal portion 260 of upstream support portion 254 is anchored to a first site of the annulus of the native valve using a tissue-engaging element, such as a tissue anchor 280 (e.g., a first tissue anchor 280a) (state A). Typically, anchor 280 is driven through upstream support portion 254 and into the tissue using an anchor driver 272, which is disposed within delivery tube 256. Typically, anchor driver 272 is slidable through the channel defined by the generally tubular shape of the upstream support portion, and is configured to move anchor 280a through at least part of that channel. For some applications, anchor 280 comprises a helical tissue anchor, and is anchored by being rotated by anchor driver 272. Anchor 280 may alternatively comprise a different type of tissue anchor, such as a harpoon-like tissue anchor.


Typically, distal portion 260 is anchored by (1) exposing the distal portion from delivery tube 256 and pressing it against the tissue of the annulus such that it deflects (e.g., bends) back and is disposed generally in front of the channel defined by the remainder of the upstream support portion that is disposed in the delivery configuration within tube 256, and (2) advancing anchor 280 distally through the upstream support portion (i.e., through distal portion 260 thereof) and into the tissue. For some applications, a plane defined by the distal portion is disposed at greater than 45 degrees with respect to longitudinal axis 258.


For some applications, during transluminal advancement, anchor 280a is disposed proximally to upstream support portion 254 (e.g., within a proximal portion of the delivery tube, or outside of the body of the subject), and driver 272 subsequently moves the anchor from a proximal end of the channel defined by the upstream support portion, through the channel. That is, driver 272 may slide anchor 280a past at least part of the longitudinal axis of upstream support portion 254 (e.g., past most of the longitudinal axis of the upstream support portion, such as past at least 80 percent of the longitudinal axis of the upstream support portion). Alternatively, during transluminal advancement, anchor 280a and a distal portion of anchor driver 272 may be already disposed within the channel defined by the upstream support portion, and the driver subsequently moves anchor 280a only slightly distally so as to drive the anchor through distal portion 260 and into the tissue. For some such applications, the delivery tube is transluminally advanced while the upstream support portion is disposed within a distal portion of the delivery tube, and the tissue anchor and the distal portion of the anchor driver are disposed within the channel.


Subsequently, upstream support portion 254 is further exposed from delivery tube 256 (e.g., by withdrawing the delivery tube proximally), and the distal end of the delivery tube is moved toward a second site of the annulus (state B). As upstream support portion 254 is progressively exposed from delivery tube 256, the upstream support portion typically progressively transitions (e.g., expands and/or unrolls) automatically toward the working configuration thereof. To facilitate such automatic transition toward the working configuration, upstream support portion 254 may comprise a frame (e.g., comprising a shape-memory material such as nitinol), which may be covered in a covering, such as a fabric.


Subsequently, a proximal portion 262 of upstream support portion 254 is anchored to the second site using a tissue anchor 280 (e.g., a second tissue anchor 280b) in a similar manner to that described for distal portion 260 (state C). Typically, during anchoring of proximal portion 262, the proximal portion is held near the distal end of delivery tube 256 by a deployment tool (e.g., slightly inside the delivery tube or just outside of the delivery tube). The deployment tool is not visible in state C; it is obscured by anchor driver 272. Following anchoring, proximal portion 262 is released by the deployment tool, and delivery tube 256 and driver 272 are withdrawn (state D).


It is to be noted that when prosthetic valve support 252 is disposed within delivery tube 256, the delivery tube and the prosthetic valve support (e.g., upstream support portion 254 thereof) share a common central longitudinal axis (e.g., are coaxial) (e.g., axis 258; FIGS. 11B-C), and that system 250 facilitates the driving of anchors through the prosthetic valve support by deflecting the portion of the prosthetic valve support that is to be anchored to intersect with the longitudinal axis, such that anchoring is possible by movement of the anchors (and anchor driver 272) along the longitudinal axis.


Prosthetic valve support 252 is typically subsequently used to facilitate implantation of a prosthetic valve, such as a prosthetic valve described hereinabove, or another prosthetic valve, e.g., by the prosthetic valve being expanded within the opening defined by the prosthetic valve support. Reference is again made to FIGS. 1A-11C. Typically, the techniques described hereinabove are performed transluminally (e.g., transfemorally). For some applications, the techniques are performed intercostally. It is therefore to be noted that the orientations and positions of the apparatus shown hereinabove with respect to atrium 6 of the subject are for clarity, and are not intended to limit the invention to a particular route to the atrium. Similarly, for some applications, the techniques described hereinabove are performed transapically, and thereby apparatus is delivered to the native valve via left ventricle 8 of the subject. It is to be further noted that, although native valve 10 is shown hereinabove as the mitral valve of the subject, the techniques described hereinabove may be used on other heart valves of the subject, such as the tricuspid valve, mutatis mutandis.


Reference is again made to FIGS. 1A-11C. For some applications, the prosthetic valve support is implanted (e.g., coupled to the native valve) without eliminating native functioning of the native leaflets. Thereby, for such applications, the prosthetic valve support (and for some such applications, the prosthetic valve) may be implanted without the use of cardiopulmonary bypass. For example:

    • Tissue-engaging elements 24 (FIGS. 1A-C) and 144 (FIGS. 5A-D) are typically configured to move with the movement of the native leaflets (e.g., by deflecting with respect to the respective upstream support portion).
    • Prosthetic valve support 202 (FIGS. 8-10) and 252 (FIG. 11) are typically anchored to the annulus of the native valve without contacting the native leaflets.


Reference is again made to FIGS. 1A-11C. For some applications, a separate prosthetic valve support is not used, but rather the upstream support portion is integral with the prosthetic valve (e.g., is coupled to the upstream end of the generally tubular valve body).


Reference is again made to FIGS. 1A-11C. It is to be noted that elements and/or techniques described herein with reference to a particular figure may be combined and/or substituted with elements and/or techniques described herein with reference to one or more other figures, mutatis mutandis. In particular, for some applications, elements of apparatus described herein are interchangeable with other elements that have the same name, mutatis mutandis. For example:

    • For some applications, prosthetic valve 148 comprises, or may be substituted with, prosthetic valve 102, prosthetic valve 180, or prosthetic valve 230, mutatis mutandis.
    • For some applications, upstream support portion 142 comprises, or may be substituted with, upstream support portion 62, upstream support portion 204, or upstream support portion 254, mutatis mutandis.
    • For some applications, tissue-engaging element 232 comprises, or may be substituted with, tissue-engaging element 24 or tissue-engaging element 144, mutatis mutandis.


It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.

Claims
  • 1. Apparatus for use with a prosthetic valve at a native valve of a heart of a subject, the apparatus comprising: a delivery tube, transluminally advanceable to the heart of the subject; anda prosthetic valve support, configured to support the prosthetic valve at the native valve, and defining an upstream support portion, the upstream support portion being a generally annular disc, and: having a working configuration in which the upstream support portion is a generally annular disc that has (1) a tissue-contacting side configured to be placed against an atrial surface of the native valve, and (2) an opposing side, and defines an opening therebetween,having a delivery configuration in which the upstream support portion is rolled up to create a channel having a central longitudinal axis, and is disposed within the delivery tube, andbeing configured to be transitioned from the delivery configuration to the working configuration by being exposed from the delivery tube, and unrolled.
  • 2. The apparatus according to claim 1, wherein, in the delivery configuration, the upstream support portion has a distal portion and a proximal portion, and shapes the channel to be an uninterrupted lumen between the distal portion and the proximal portion.
  • 3. The apparatus according to claim 1, wherein the delivery tube is configured to retain the upstream support portion in the delivery configuration, and the upstream support portion is configured to automatically transition toward the working configuration by automatically unrolling upon becoming exposed from the delivery tube.
  • 4. The apparatus according to claim 1, wherein, while the upstream support portion is in the delivery configuration, at any given part of the upstream support portion, the opposing side of the upstream support portion is disposed closer to the central longitudinal axis than is the tissue-contacting side.
  • 5. The apparatus according to claim 1, wherein, while the upstream support portion is in the delivery configuration, the central longitudinal axis of the channel is collinear with a central longitudinal axis of the delivery tube.
  • 6. A method for use with a prosthetic valve at a native valve of a heart of a subject, comprising: transluminally advancing, to a heart valve of the subject, a prosthetic valve support that defines an upstream support portion, the advancing being while the upstream support portion is in a delivery configuration in which the upstream support portion (i) is rolled up to create a channel having a central longitudinal axis, and (ii) is disposed within a delivery tube;subsequently, facilitating transition of the upstream support portion into a working configuration by exposing the upstream support portion from the delivery tube and facilitating unrolling of the upstream support portion, the working configuration being a configuration in which: the upstream support portion is a generally annular disc that has (1) a tissue-contacting side, and (2) an opposing side,the upstream support portion defines an opening between the tissue-contacting side and the opposing side, andthe tissue-contacting side is disposed against an atrial surface of the native valve; andusing the prosthetic valve support, supporting the prosthetic valve at the native valve.
  • 7. The method according to claim 6, wherein facilitating transition of the upstream support portion into the working configuration comprises exposing the upstream support portion from the delivery tube such that the upstream support portion automatically unrolls.
  • 8. The method according to claim 6, wherein, in the delivery configuration, the upstream support portion has a proximal portion and a distal portion, the channel being defined between the proximal portion and the distal portion, and wherein the method further comprises pressing the distal portion against the annulus such that the distal portion deflects with respect to the delivery tube.
  • 9. The method according to claim 6, wherein, in the delivery configuration, the upstream support portion has a proximal portion and a distal portion, the channel being defined between the proximal portion and the distal portion, and wherein the method further comprises pressing the distal portion against the annulus such that the distal portion deflects with respect to the proximal portion.
CROSS-REFERENCES TO RELATED APPLICATIONS

The present application is a Continuation of U.S. patent application Ser. No. 14/161,921 to HaCohen et al., filed Jan. 23, 2014, and entitled “Anchoring of prosthetic valve supports,” which published as U.S. 2014/0207231, and which: (1) claims priority from U.S. provisional Patent Application 61/756,034 to Hacohen et al., filed Jan. 24, 2013, and entitled “Tissue-engaging elements”; and U.S. Provisional Patent Application 61/756,049 to Hacohen et al., filed Jan. 24, 2013, and entitled “Ventricularly-anchored prosthetic valve support”, and(2) is related to: U.S. patent application publication 201210022639 to Hacohen et al,, filed Jul. 21, 2010 (now U.S. Pat. No. 9,132,009);U.S. patent application publication 2012/0022640 to Gross et al., filed Feb. 24, 2011 (now U.S. Pat. No. 8,992,604);U.S. patent application Ser. No. 13/811,308 to Gross et al., filed Jan. 21, 2013, which published as U.S. 2013/0172992 (U.S. Pat No. 9,017,399);U.S. patent application Ser. No. 13/412,814 to Gross et al., filed Mar. 6, 2012, which published as U.S. 2013/0035759 (now U.S. Pat. No. 8,852,272);PCT patent application IL2012/000292 to Gross et al., filed Aug. 5, 2012, which published as WO/2013/021374;PCT patent application IL2012/000293 to Gross et al., filed Aug. 5, 2012, which published as WO/2013/021375; anda PCT patent application to HaCohen et al., entitled “Ventricularly-anchored prosthetic valves”, filed on even date herewith, which was assigned PCT application number IL2014/050087, and which published as WO/2014/115149.all of which are incorporated herein by reference.

US Referenced Citations (835)
Number Name Date Kind
4261342 Aranguren Duo Apr 1981 A
4423525 Vallana et al. Jan 1984 A
4853986 Allen Aug 1989 A
4892541 Alonso Jan 1990 A
5108420 Marks Apr 1992 A
5314473 Godin May 1994 A
5405378 Strecker Apr 1995 A
5443500 Sigwart Aug 1995 A
5607444 Lam Mar 1997 A
5607470 Milo Mar 1997 A
5647857 Anderson et al. Jul 1997 A
5702397 Goble et al. Dec 1997 A
5765682 Bley et al. Jun 1998 A
5776140 Cottone Jul 1998 A
5868777 Lam Feb 1999 A
5873906 Lau et al. Feb 1999 A
5954766 Zadno-Azizi et al. Sep 1999 A
5957949 Leonhardt Sep 1999 A
5980565 Jayaraman Nov 1999 A
6010530 Goicoechea Jan 2000 A
6019787 Richard et al. Feb 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6074417 Peredo Jun 2000 A
6120534 Ruiz Sep 2000 A
6165210 Lau et al. Dec 2000 A
6187020 Zegdi et al. Feb 2001 B1
6193745 Fogarty et al. Feb 2001 B1
6264700 Kilcoyne et al. Jul 2001 B1
6287339 Vazquez et al. Sep 2001 B1
6332893 Mortier et al. Dec 2001 B1
6334873 Lane et al. Jan 2002 B1
6350278 Lenker et al. Feb 2002 B1
6352561 Leopold et al. Mar 2002 B1
6402780 Williamson, IV et al. Jun 2002 B2
6419696 Ortiz et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6530952 Vesely Mar 2003 B2
6540782 Snyders Apr 2003 B1
6551350 Thornton et al. Apr 2003 B1
6558396 Inoue May 2003 B1
6558418 Carpentier et al. May 2003 B2
6582464 Gabbay Jun 2003 B2
6652556 VanTassel et al. Nov 2003 B1
6669724 Park et al. Dec 2003 B2
6699256 Logan et al. Mar 2004 B1
6716244 Klaco Apr 2004 B2
6719781 Kim Apr 2004 B1
6730118 Spenser et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6764514 Li Jul 2004 B1
6764518 Godin Jul 2004 B2
6767362 Schreck Jul 2004 B2
6797002 Spence et al. Sep 2004 B2
6821297 Snyders Nov 2004 B2
6830585 Artof et al. Dec 2004 B1
6830638 Boylan et al. Dec 2004 B2
6951571 Srivastava Oct 2005 B1
6960217 Bolduc Nov 2005 B2
6964684 Ortiz et al. Nov 2005 B2
7011681 Vesely Mar 2006 B2
7018406 Seguin et al. Mar 2006 B2
7041132 Quijano et al. May 2006 B2
7077861 Spence Jul 2006 B2
7101336 Artof et al. Sep 2006 B2
7101395 Tremulis et al. Sep 2006 B2
7137184 Schreck Nov 2006 B2
7172625 Shu et al. Feb 2007 B2
7198646 Figulla et al. Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7288111 Holloway et al. Oct 2007 B1
7316716 Egan Jan 2008 B2
7329279 Haug et al. Feb 2008 B2
7335213 Hyde et al. Feb 2008 B1
7351256 Hojeibane et al. Apr 2008 B2
7374571 Pease et al. May 2008 B2
7374573 Gabbay May 2008 B2
7377938 Sarac et al. May 2008 B2
7404824 Webler et al. Jul 2008 B1
7422603 Lane Sep 2008 B2
7429269 Schwammenthal et al. Sep 2008 B2
7442204 Schwammenthal et al. Oct 2008 B2
7445630 Lasninski et al. Nov 2008 B2
7455677 Vargas et al. Nov 2008 B2
7455688 Furst et al. Nov 2008 B2
7462162 Phan et al. Dec 2008 B2
7481838 Carpentier et al. Jan 2009 B2
7510575 Spenser et al. Mar 2009 B2
7513909 Lane et al. Apr 2009 B2
7527646 Rahdert et al. May 2009 B2
7582111 Krolik et al. Sep 2009 B2
7585321 Cribier Sep 2009 B2
7625403 Krivoruchko Dec 2009 B2
7632302 Vreeman et al. Dec 2009 B2
7648528 Styrc Jan 2010 B2
7682380 Thornton et al. Mar 2010 B2
7708775 Rowe et al. May 2010 B2
7717952 Case et al. May 2010 B2
7717955 Lane et al. May 2010 B2
7731741 Eidenschink Jun 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7753922 Starksen Jul 2010 B2
7758595 Allen et al. Jul 2010 B2
7758632 Hojeibane et al. Jul 2010 B2
7771467 Svensson Aug 2010 B2
7771469 Liddicoat Aug 2010 B2
7776083 Vesely Aug 2010 B2
7780726 Seguin Aug 2010 B2
7799069 Bailey et al. Sep 2010 B2
7803181 Furst et al. Sep 2010 B2
7837645 Bessler et al. Nov 2010 B2
7837727 Goetz et al. Nov 2010 B2
7842081 Yadin Nov 2010 B2
7850725 Vardi et al. Dec 2010 B2
7871432 Bergin Jan 2011 B2
7871436 Ryan et al. Jan 2011 B2
7887583 Macoviak Feb 2011 B2
7892281 Seguin et al. Feb 2011 B2
7896915 Guyenot et al. Mar 2011 B2
7914544 Nguyen et al. Mar 2011 B2
7914569 Nguyen et al. Mar 2011 B2
7927370 Webler et al. Apr 2011 B2
7942927 Kaye et al. May 2011 B2
7947072 Yang et al. May 2011 B2
7947075 Goetz et al. May 2011 B2
7955375 Agnew Jun 2011 B2
7955377 Melsheimer Jun 2011 B2
7955384 Rafiee et al. Jun 2011 B2
7959672 Salahieh et al. Jun 2011 B2
7967833 Sterman et al. Jun 2011 B2
7967857 Lane Jun 2011 B2
7981151 Rowe Jul 2011 B2
7981153 Fogarty et al. Jul 2011 B2
7992567 Hirotsuka et al. Aug 2011 B2
7993393 Carpentier et al. Aug 2011 B2
8002825 Letac et al. Aug 2011 B2
8002826 Seguin Aug 2011 B2
8016877 Seguin et al. Sep 2011 B2
8016882 Macoviak et al. Sep 2011 B2
8021420 Dolan Sep 2011 B2
8021421 Fogarty et al. Sep 2011 B2
8029518 Goldfarb et al. Oct 2011 B2
8029557 Sobrino-Serrano et al. Oct 2011 B2
8029564 Johnson et al. Oct 2011 B2
8034104 Carpentier et al. Oct 2011 B2
8038720 Wallace et al. Oct 2011 B2
8043360 McNamara et al. Oct 2011 B2
8048138 Sullivan et al. Nov 2011 B2
8048140 Purdy Nov 2011 B2
8048153 Salahieh et al. Nov 2011 B2
8052741 Bruszewski et al. Nov 2011 B2
8057493 Goldfarb et al. Nov 2011 B2
8057532 Hoffman Nov 2011 B2
8057540 Letac et al. Nov 2011 B2
8062355 Figulla et al. Nov 2011 B2
8062359 Marquez et al. Nov 2011 B2
8070708 Rottenberg et al. Dec 2011 B2
8070800 Lock et al. Dec 2011 B2
8070802 Lamphere et al. Dec 2011 B2
8070804 Hyde et al. Dec 2011 B2
8075611 Millwee et al. Dec 2011 B2
8080054 Rowe Dec 2011 B2
8083793 Lane et al. Dec 2011 B2
D652927 Braido et al. Jan 2012 S
D653341 Braido et al. Jan 2012 S
8092518 Schreck Jan 2012 B2
8092520 Quadri Jan 2012 B2
8092521 Figulla et al. Jan 2012 B2
8105377 Liddicoat Jan 2012 B2
8109996 Stacchino et al. Feb 2012 B2
8118866 Herrmann et al. Feb 2012 B2
8136218 Millwee et al. Mar 2012 B2
8137398 Tuval et al. Mar 2012 B2
8142492 Forster et al. Mar 2012 B2
8142494 Rahdert et al. Mar 2012 B2
8142496 Berreklouw Mar 2012 B2
8142497 Friedman Mar 2012 B2
8147504 Ino et al. Apr 2012 B2
8157852 Bloom et al. Apr 2012 B2
8157853 Laske et al. Apr 2012 B2
8157860 McNamara et al. Apr 2012 B2
8163008 Wilson et al. Apr 2012 B2
8163014 Lane et al. Apr 2012 B2
D660433 Braido et al. May 2012 S
D660967 Braido et al. May 2012 S
8167894 Miles et al. May 2012 B2
8167932 Bourang et al. May 2012 B2
8167935 McGuckin, Jr. et al. May 2012 B2
8172896 McNamara May 2012 B2
8172898 Alferness et al. May 2012 B2
8177836 Lee et al. May 2012 B2
8182528 Salahieh et al. May 2012 B2
8211169 Lane et al. Jul 2012 B2
8221492 Case et al. Jul 2012 B2
8221493 Boyle et al. Jul 2012 B2
8226710 Nguyen et al. Jul 2012 B2
8231670 Salahleh et al. Jul 2012 B2
8236045 Benichou et al. Aug 2012 B2
8236049 Rowe et al. Aug 2012 B2
8252042 McNamara et al. Aug 2012 B2
8252051 Chau et al. Aug 2012 B2
8252052 Salahieh et al. Aug 2012 B2
8257390 Carley et al. Sep 2012 B2
8267988 Hamer et al. Sep 2012 B2
8277501 Chaleklan et al. Oct 2012 B2
8287591 Keidar et al. Oct 2012 B2
8298280 Yadin et al. Oct 2012 B2
8308798 Pintor et al. Nov 2012 B2
8317853 Agnew Nov 2012 B2
8317855 Gregorich et al. Nov 2012 B2
8323335 Rowe et al. Dec 2012 B2
8328868 Paul et al. Dec 2012 B2
8337541 Quadri et al. Dec 2012 B2
8343174 Goldfarb et al. Jan 2013 B2
8343213 Salahieh et al. Jan 2013 B2
8403981 Forster et al. Mar 2013 B2
8403983 Quadri et al. Mar 2013 B2
8408214 Spenser Apr 2013 B2
8414644 Quadri et al. Apr 2013 B2
8425593 Braido et al. Apr 2013 B2
8430934 Das Apr 2013 B2
8444689 Zhang May 2013 B2
8449599 Chau et al. May 2013 B2
8449625 Campbell et al. May 2013 B2
8454686 Alkhatib Jun 2013 B2
8474460 Barrett et al. Jul 2013 B2
8500821 Sobrino-Serrano et al. Aug 2013 B2
8529431 Baker Sep 2013 B2
8545544 Spenser et al. Oct 2013 B2
8551161 Dgian Oct 2013 B2
8562672 Bonhoeffer et al. Oct 2013 B2
8579964 Lane et al. Nov 2013 B2
8579965 Bonhoeffer et al. Nov 2013 B2
8585755 Chau et al. Nov 2013 B2
8585756 Bonhoeffer et al. Nov 2013 B2
8591460 Wilson et al. Nov 2013 B2
8591570 Revuelta et al. Nov 2013 B2
8623075 Murray, III et al. Jan 2014 B2
8628569 Benichou et al. Jan 2014 B2
8628570 Seguin Jan 2014 B2
8628571 Hacohen et al. Jan 2014 B1
8652203 Quadri et al. Feb 2014 B2
8657672 Sequin Feb 2014 B2
8673020 Sobrino-Serrano et al. Mar 2014 B2
8679174 Ottma et al. Mar 2014 B2
8685086 Navia et al. Apr 2014 B2
8696742 Pintor et al. Apr 2014 B2
8728155 Montorfano et al. May 2014 B2
8747460 Tuval et al. Jun 2014 B2
8771345 Tuval et al. Jul 2014 B2
8784472 Eidenschink Jul 2014 B2
8784481 Alkhatib et al. Jul 2014 B2
8795355 Alkhatib Aug 2014 B2
8795356 Quadri et al. Aug 2014 B2
8795357 Yohanan et al. Aug 2014 B2
8808366 Braido et al. Aug 2014 B2
8840684 Karapetian et al. Sep 2014 B2
8852261 White Oct 2014 B2
8852272 Gross et al. Oct 2014 B2
8870948 Erzberger et al. Oct 2014 B1
8870949 Rowe Oct 2014 B2
8870950 Hacohen Oct 2014 B2
8876800 Behan Nov 2014 B2
8888843 Khairkhahan et al. Nov 2014 B2
8894702 Quadri et al. Nov 2014 B2
8906083 Obermiller et al. Dec 2014 B2
8911455 Quadri et al. Dec 2014 B2
8911489 Ben-Muvhar Dec 2014 B2
8932343 Alkhatib et al. Jan 2015 B2
8961595 Alkhatib Feb 2015 B2
8979922 Jayasinghe et al. Mar 2015 B2
8986373 Chau et al. Mar 2015 B2
8986375 Garde et al. Mar 2015 B2
8992608 Haug et al. Mar 2015 B2
8998982 Richter et al. Apr 2015 B2
9005273 Salahieh et al. Apr 2015 B2
D730520 Braido et al. May 2015 S
D730521 Braido et al. May 2015 S
9023100 Quadri et al. May 2015 B2
9034032 McLean et al. May 2015 B2
9034033 McLean et al. May 2015 B2
9039757 McLean et al. May 2015 B2
D732666 Nguyen et al. Jun 2015 S
9050188 Schweich, Jr. et al. Jun 2015 B2
9072603 Tuval et al. Jul 2015 B2
9084676 Chau et al. Jul 2015 B2
9095434 Rowe Aug 2015 B2
9125738 Figulla et al. Sep 2015 B2
9125740 Morriss et al. Sep 2015 B2
9132006 Spenser et al. Sep 2015 B2
9138312 Tuval et al. Sep 2015 B2
9173738 Murray, III et al. Nov 2015 B2
9220594 Braido et al. Dec 2015 B2
9226820 Braido et al. Jan 2016 B2
9226839 Kariniemi et al. Jan 2016 B1
9232995 Kovalsky et al. Jan 2016 B2
9241790 Lane et al. Jan 2016 B2
9241791 Braido et al. Jan 2016 B2
9241792 Benichou et al. Jan 2016 B2
9241794 Braido et al. Jan 2016 B2
9248014 Lane et al. Feb 2016 B2
9289290 Alkhatib et al. Mar 2016 B2
9289291 Gorman, III et al. Mar 2016 B2
9295550 Nguyen et al. Mar 2016 B2
9295552 McLean et al. Mar 2016 B2
9301836 Buchbinder et al. Apr 2016 B2
D755384 Pesce et al. May 2016 S
9326852 Spenser May 2016 B2
9326876 Acosta et al. May 2016 B2
9345573 Nyuli et al. May 2016 B2
9387078 Gross et al. Jul 2016 B2
9421098 Gifford et al. Aug 2016 B2
9427303 Liddy et al. Aug 2016 B2
9427316 Schweich, Jr. et al. Aug 2016 B2
9439757 Wallace et al. Sep 2016 B2
9474638 Robinson et al. Oct 2016 B2
9480559 Vidlund et al. Nov 2016 B2
9492273 Wallace et al. Nov 2016 B2
9498314 Behan Nov 2016 B2
9532870 Cooper et al. Jan 2017 B2
9554897 Lane et al. Jan 2017 B2
9554899 Granada et al. Jan 2017 B2
9561103 Granada et al. Feb 2017 B2
9566152 Schweih, Jr. et al. Feb 2017 B2
9629716 Seguin Apr 2017 B2
9662203 Sheahan et al. May 2017 B2
9681952 Hacohen et al. Jun 2017 B2
9717591 Chau et al. Aug 2017 B2
9743932 Amlplatz et al. Aug 2017 B2
9763657 Hacohen et al. Sep 2017 B2
9763817 Roeder Sep 2017 B2
D800908 Hariton et al. Oct 2017 S
9788941 Hacohen Oct 2017 B2
10010414 Cooper et al. Jul 2018 B2
10143552 Wallace et al. Dec 2018 B2
10149761 Granada et al. Dec 2018 B2
10154906 Granada et al. Dec 2018 B2
10182908 Tubishevitz et al. Jan 2019 B2
10206668 McGoldrick Feb 2019 B2
10226341 Gross et al. Mar 2019 B2
10245143 Gross et al. Apr 2019 B2
10258471 Lutter et al. Apr 2019 B2
10321995 Christianson et al. Jun 2019 B1
10327895 Lozonschi et al. Jun 2019 B2
10376361 Gross et al. Aug 2019 B2
10456256 Braido Oct 2019 B2
10531872 Hacohen et al. Jan 2020 B2
10548731 Lashinski et al. Feb 2020 B2
20010002445 Vesely May 2001 A1
20010021872 Bailey et al. Sep 2001 A1
20010056295 Solem Dec 2001 A1
20020032481 Gabbay Mar 2002 A1
20020099436 Thornton et al. Jul 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020177894 Acosta et al. Nov 2002 A1
20030009236 Godin Jan 2003 A1
20030036791 Philipp et al. Feb 2003 A1
20030060846 Egnelov Mar 2003 A1
20030060875 Wittens Mar 2003 A1
20030069635 Cartledge et al. Apr 2003 A1
20030074052 Besselink Apr 2003 A1
20030083742 Spence et al. May 2003 A1
20030105519 Fasol et al. Jun 2003 A1
20030158578 Pantages et al. Aug 2003 A1
20040010272 Manetakis et al. Jan 2004 A1
20040039414 Carley et al. Feb 2004 A1
20040093060 Seguin et al. May 2004 A1
20040122503 Campbell et al. Jun 2004 A1
20040122514 Fogarty et al. Jun 2004 A1
20040133267 Lane Jul 2004 A1
20040143315 Bruun et al. Jul 2004 A1
20040176839 Huynh et al. Sep 2004 A1
20040186558 Pavenik et al. Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040186566 Hindrichs et al. Sep 2004 A1
20040210244 Vargas et al. Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040220593 Greenhalgh Nov 2004 A1
20040225354 Allen et al. Nov 2004 A1
20040249433 Freitag Dec 2004 A1
20040260389 Case et al. Dec 2004 A1
20040260394 Douk et al. Dec 2004 A1
20050004668 Aklog et al. Jan 2005 A1
20050021056 St. Goar et al. Jan 2005 A1
20050027305 Shiu et al. Feb 2005 A1
20050038494 Eidenschink Feb 2005 A1
20050055086 Stobie Mar 2005 A1
20050075731 Artof et al. Apr 2005 A1
20050080430 Wright, Jr. et al. Apr 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050149160 McFerran Jul 2005 A1
20050154443 Linder et al. Jul 2005 A1
20050182486 Gabbay et al. Aug 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203549 Realyvasquez Sep 2005 A1
20050216079 MaCoviak Sep 2005 A1
20050234508 Cummins et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050251251 Cribier Nov 2005 A1
20050267573 Macoviak et al. Dec 2005 A9
20060004439 Spenser et al. Jan 2006 A1
20060004469 Sokel Jan 2006 A1
20060015171 Armstrong Jan 2006 A1
20060020327 Lashinski et al. Jan 2006 A1
20060020333 Lashinski et al. Jan 2006 A1
20060041189 Vancaillie Feb 2006 A1
20060047297 Case Mar 2006 A1
20060052867 Revuelta et al. Mar 2006 A1
20060089627 Burnett et al. Apr 2006 A1
20060111773 Rittgers et al. May 2006 A1
20060116750 Hebert et al. Jun 2006 A1
20060135964 Vesely Jun 2006 A1
20060155357 Melsheimer Jul 2006 A1
20060178700 Quinn Aug 2006 A1
20060178740 Stacchino et al. Aug 2006 A1
20060190036 Wendel et al. Aug 2006 A1
20060190038 Carley et al. Aug 2006 A1
20060195184 Lane et al. Aug 2006 A1
20060201519 Frazier et al. Sep 2006 A1
20060212111 Case et al. Sep 2006 A1
20060241656 Starksen et al. Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060241748 Lee et al. Oct 2006 A1
20060247680 Amplatz et al. Nov 2006 A1
20060253191 Salahieh et al. Nov 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060271166 Thill et al. Nov 2006 A1
20060271171 McQuinn et al. Nov 2006 A1
20060287719 Rowe et al. Dec 2006 A1
20070016288 Gurskis et al. Jan 2007 A1
20070027528 Agnew Feb 2007 A1
20070027549 Godin Feb 2007 A1
20070038295 Case et al. Feb 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070055340 Pryor Mar 2007 A1
20070056346 Spenser et al. Mar 2007 A1
20070078510 Ryan Apr 2007 A1
20070112422 Dehdashtian May 2007 A1
20070118151 Davidson May 2007 A1
20070162103 Case et al. Jul 2007 A1
20070162107 Haug et al. Jul 2007 A1
20070162111 Fukamachi et al. Jul 2007 A1
20070173932 Cali et al. Jul 2007 A1
20070198077 Cully et al. Aug 2007 A1
20070198097 Zegdi Aug 2007 A1
20070213810 Newhauser et al. Sep 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070219630 Chu Sep 2007 A1
20070225759 Thommen et al. Sep 2007 A1
20070225760 Moszner et al. Sep 2007 A1
20070233186 Meng Oct 2007 A1
20070233237 Kriveruchko Oct 2007 A1
20070239272 Navia et al. Oct 2007 A1
20070255400 Parravicini et al. Nov 2007 A1
20080004688 Spenser et al. Jan 2008 A1
20080004697 Lichtenstein et al. Jan 2008 A1
20080051703 Thornton et al. Feb 2008 A1
20080071361 Tuval et al. Mar 2008 A1
20080071363 Tuval et al. Mar 2008 A1
20080071366 Tuval et al. Mar 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080077235 Kirson Mar 2008 A1
20080082083 Forde et al. Apr 2008 A1
20080082159 Tseng et al. Apr 2008 A1
20080082166 Styrc et al. Apr 2008 A1
20080086164 Rowe Apr 2008 A1
20080086204 Rankin Apr 2008 A1
20080091261 Long et al. Apr 2008 A1
20080097595 Gabbay Apr 2008 A1
20080132989 Snow et al. Jun 2008 A1
20080140003 Bei et al. Jun 2008 A1
20080147182 Righini et al. Jun 2008 A1
20080161910 Revuelta et al. Jul 2008 A1
20080167705 Agnew Jul 2008 A1
20080167714 St. Goar et al. Jul 2008 A1
20080188929 Schreck Aug 2008 A1
20080195200 Vidiund et al. Aug 2008 A1
20080200980 Robin Aug 2008 A1
20080208332 Lamphere et al. Aug 2008 A1
20080221672 Lamphere et al. Sep 2008 A1
20080234814 Salahieh et al. Sep 2008 A1
20080243245 Thambar et al. Oct 2008 A1
20080255580 Hoffman et al. Oct 2008 A1
20080262609 Gross et al. Oct 2008 A1
20080269879 Sathe et al. Oct 2008 A1
20080281411 Berreklouw Nov 2008 A1
20080294234 Hartley et al. Nov 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090036966 O'Connor et al. Feb 2009 A1
20090054969 Salahieh et al. Feb 2009 A1
20090088836 Bishop et al. Apr 2009 A1
20090099554 Forster et al. Apr 2009 A1
20090099650 Bolduc et al. Apr 2009 A1
20090112159 Slattery et al. Apr 2009 A1
20090125098 Chuter May 2009 A1
20090157175 Benichou Jun 2009 A1
20090171363 Chevron Jul 2009 A1
20090177278 Spence Jul 2009 A1
20090210052 Forster et al. Aug 2009 A1
20090222081 Linder et al. Sep 2009 A1
20090240320 Tuval et al. Sep 2009 A1
20090259306 Rowe Oct 2009 A1
20090264859 Mas Oct 2009 A1
20090264994 Saadat Oct 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090281619 Le et al. Nov 2009 A1
20090299449 Styrc Dec 2009 A1
20090306768 Quadri Dec 2009 A1
20090319037 Rowe et al. Dec 2009 A1
20100023117 Yoganathan et al. Jan 2010 A1
20100023120 Holecek et al. Jan 2010 A1
20100036479 Hill et al. Feb 2010 A1
20100049313 Alon et al. Feb 2010 A1
20100069852 Kelley Mar 2010 A1
20100076548 Konno Mar 2010 A1
20100100167 Bortlein et al. Apr 2010 A1
20100114299 Ben Muvhar et al. May 2010 A1
20100131054 Tuval et al. May 2010 A1
20100137979 Tuval et al. Jun 2010 A1
20100160958 Clark Jun 2010 A1
20100161036 Pintor et al. Jun 2010 A1
20100161042 Maisano et al. Jun 2010 A1
20100174363 Castro Jul 2010 A1
20100179643 Shalev Jul 2010 A1
20100179648 Richter et al. Jul 2010 A1
20100179649 Richter et al. Jul 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100222810 DeBeer et al. Sep 2010 A1
20100228285 Miles et al. Sep 2010 A1
20100234940 Dolan Sep 2010 A1
20100249908 Chau et al. Sep 2010 A1
20100249917 Zhang Sep 2010 A1
20100256737 Pollock et al. Oct 2010 A1
20100262232 Annest Oct 2010 A1
20100230603 Maisano et al. Nov 2010 A1
20100280606 Naor Nov 2010 A1
20100312333 Navia et al. Dec 2010 A1
20100324595 Linder et al. Dec 2010 A1
20100331971 Keranen et al. Dec 2010 A1
20110004296 Lutter et al. Jan 2011 A1
20110004299 Navia et al. Jan 2011 A1
20110015729 Jimenez et al. Jan 2011 A1
20110015731 Carpentier et al. Jan 2011 A1
20110021985 Spargias Jan 2011 A1
20110022165 Oba et al. Jan 2011 A1
20110029067 McGuckin, Jr. Feb 2011 A1
20110029072 Gabbay Feb 2011 A1
20110040374 Goetz et al. Feb 2011 A1
20110040375 Letac et al. Feb 2011 A1
20110046662 Moszner et al. Feb 2011 A1
20110054466 Rothstein et al. Mar 2011 A1
20110054596 Taylor Mar 2011 A1
20110054598 Johnson Mar 2011 A1
20110071626 Wright et al. Mar 2011 A1
20110077730 Fenster Mar 2011 A1
20110082538 Dahlgren et al. Apr 2011 A1
20110087322 Letac et al. Apr 2011 A1
20110093063 Schreck Apr 2011 A1
20110106247 Miller et al. May 2011 A1
20110112625 Ben-Muvhar et al. May 2011 A1
20110112632 Chau et al. May 2011 A1
20110118830 Liddicoat et al. May 2011 A1
20110125257 Seguin et al. May 2011 A1
20110125258 Centola May 2011 A1
20110137397 Chau Jun 2011 A1
20110137409 Yang et al. Jun 2011 A1
20110137410 Hacohen Jun 2011 A1
20110144742 Madrid et al. Jun 2011 A1
20110166636 Rowe Jul 2011 A1
20110172784 Richter et al. Jul 2011 A1
20110178597 Navia et al. Jul 2011 A9
20110184510 Maisano et al. Jul 2011 A1
20110190877 Lane et al. Aug 2011 A1
20110190879 Bobo et al. Aug 2011 A1
20110202076 Richter Aug 2011 A1
20110208283 Rust Aug 2011 A1
20110208293 Tabor Aug 2011 A1
20110208298 Tuval et al. Aug 2011 A1
20110213459 Garrison et al. Sep 2011 A1
20110213461 Seguin et al. Sep 2011 A1
20110218619 Benichou et al. Sep 2011 A1
20110218620 Mein et al. Sep 2011 A1
20110224785 Hacohen Sep 2011 A1
20110238094 Thomas Sep 2011 A1
20110238159 Guyenot et al. Sep 2011 A1
20110245911 Quill et al. Oct 2011 A1
20110245917 Savage et al. Oct 2011 A1
20110251675 Dwork Oct 2011 A1
20110251676 Sweeney et al. Oct 2011 A1
20110251678 Eidenschink et al. Oct 2011 A1
20110251679 Wiemeyer et al. Oct 2011 A1
20110251680 Tran et al. Oct 2011 A1
20110251682 Murray, III et al. Oct 2011 A1
20110251683 Tabor Oct 2011 A1
20110257721 Tabor Oct 2011 A1
20110257729 Spenser et al. Oct 2011 A1
20110257736 Marquez et al. Oct 2011 A1
20110257737 Fogarty et al. Oct 2011 A1
20110264191 Rothstein Oct 2011 A1
20110264196 Savage et al. Oct 2011 A1
20110264198 Murray, III et al. Oct 2011 A1
20110264199 Tran et al. Oct 2011 A1
20110264200 Tran et al. Oct 2011 A1
20110264201 Yeung et al. Oct 2011 A1
20110264202 Murray, III et al. Oct 2011 A1
20110264203 Dwork et al. Oct 2011 A1
20110264206 Tabor Oct 2011 A1
20110264208 Duffy et al. Oct 2011 A1
20110270276 Rothstein et al. Nov 2011 A1
20110271967 Mortier et al. Nov 2011 A1
20110282438 Drews et al. Nov 2011 A1
20110282439 Thill et al. Nov 2011 A1
20110282440 Cao et al. Nov 2011 A1
20110283514 Fogarty et al. Nov 2011 A1
20110288632 White Nov 2011 A1
20110288634 Tuval et al. Nov 2011 A1
20110295354 Bueche et al. Dec 2011 A1
20110295363 Girard et al. Dec 2011 A1
20110301688 Dolan Dec 2011 A1
20110301701 Padala et al. Dec 2011 A1
20110301702 Rust et al. Dec 2011 A1
20110313452 Carley et al. Dec 2011 A1
20110313515 Quadri et al. Dec 2011 A1
20110319989 Lane et al. Dec 2011 A1
20110319991 Hariton et al. Dec 2011 A1
20120010694 Lutter et al. Jan 2012 A1
20120016468 Robin et al. Jan 2012 A1
20120022629 Perera et al. Jan 2012 A1
20120022633 Olson et al. Jan 2012 A1
20120022637 Ben-Muvhar Jan 2012 A1
20120022639 Hacohen et al. Jan 2012 A1
20120022640 Gross et al. Jan 2012 A1
20120035703 Lutter et al. Feb 2012 A1
20120035713 Lutter et al. Feb 2012 A1
20120035722 Tuval Feb 2012 A1
20120041547 Duffy et al. Feb 2012 A1
20120041551 Spenser et al. Feb 2012 A1
20120046738 Lau et al. Feb 2012 A1
20120046742 Tuval et al. Feb 2012 A1
20120053676 Ku et al. Mar 2012 A1
20120053680 Bolling Mar 2012 A1
20120053682 Kovalsky et al. Mar 2012 A1
20120053688 Fogarty et al. Mar 2012 A1
20120059454 Millwee et al. Mar 2012 A1
20120059458 Buchbinder et al. Mar 2012 A1
20120065464 Ellis et al. Mar 2012 A1
20120078237 Wang et al. Mar 2012 A1
20120078353 Quadri et al. Mar 2012 A1
20120078357 Conklin Mar 2012 A1
20120083832 Delaloye et al. Apr 2012 A1
20120083839 Letac et al. Apr 2012 A1
20120083879 Eberhardt et al. Apr 2012 A1
20120089223 Nguyen et al. Apr 2012 A1
20120101570 Tuval et al. Apr 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120101572 Kovalsky et al. Apr 2012 A1
20120123511 Brown May 2012 A1
20120123530 Carpentier et al. May 2012 A1
20120130473 Norris et al. May 2012 A1
20120130474 Buckley May 2012 A1
20120130475 Shaw May 2012 A1
20120136434 Carpentier et al. May 2012 A1
20120150218 Sandgren et al. Jun 2012 A1
20120165915 Meisheimer et al. Jun 2012 A1
20120179244 Schankereli et al. Jul 2012 A1
20120197292 Chin-Chen et al. Aug 2012 A1
20120283824 Lutter et al. Nov 2012 A1
20120290062 McNamara et al. Nov 2012 A1
20120296360 Norris et al. Nov 2012 A1
20120300063 Majkrzak et al. Nov 2012 A1
20120310328 Olson Dec 2012 A1
20120323316 Chau et al. Dec 2012 A1
20120330408 Hillukka et al. Dec 2012 A1
20130006347 McHugo Jan 2013 A1
20130018450 Hunt Jan 2013 A1
20130018458 Yohanan et al. Jan 2013 A1
20130035759 Gross et al. Feb 2013 A1
20130041451 Patterson et al. Feb 2013 A1
20130046373 Cartledge et al. Feb 2013 A1
20130079872 Gallagher Mar 2013 A1
20130116780 Miller et al. May 2013 A1
20130123896 Bloss et al. May 2013 A1
20130123900 Eblacas et al. May 2013 A1
20130150915 Crawford et al. Jun 2013 A1
20130150956 Yohanan et al. Jun 2013 A1
20130158647 Norris et al. Jun 2013 A1
20130166017 Cartledge et al. Jun 2013 A1
20130166022 Conklin Jun 2013 A1
20130172978 Vidlund et al. Jul 2013 A1
20130172992 Gross et al. Jul 2013 A1
20130190861 Chau et al. Jul 2013 A1
20130211501 Buckley et al. Aug 2013 A1
20130245742 Norris Sep 2013 A1
20130261737 Costello Oct 2013 A1
20130261738 Clague et al. Oct 2013 A1
20130289711 Liddy et al. Oct 2013 A1
20130297013 Klima et al. Nov 2013 A1
20130304197 Buchbinder et al. Nov 2013 A1
20130304200 McLean et al. Nov 2013 A1
20130310928 Morriss et al. Nov 2013 A1
20130331929 Mitre et al. Dec 2013 A1
20140000112 Braido et al. Jan 2014 A1
20140005778 Buchbinder et al. Jan 2014 A1
20140018911 Zhou et al. Jan 2014 A1
20140018915 Biadillah et al. Jan 2014 A1
20140031928 Murphy et al. Jan 2014 A1
20140046430 Shaw Feb 2014 A1
20140052237 Lane et al. Feb 2014 A1
20140081376 Burkart et al. Mar 2014 A1
20140106951 Brandon Apr 2014 A1
20140120287 Jacoby et al. May 2014 A1
20140121749 Roeder May 2014 A1
20140121763 Duffy et al. May 2014 A1
20140135894 Norris et al. May 2014 A1
20140135895 Andress et al. May 2014 A1
20140142681 Norris May 2014 A1
20140142688 Duffy et al. May 2014 A1
20140148891 Johnson May 2014 A1
20140163690 White Jun 2014 A1
20140172069 Roeder et al. Jun 2014 A1
20140172077 Bruchman et al. Jun 2014 A1
20140172082 Bruchman et al. Jun 2014 A1
20140188210 Beard et al. Jul 2014 A1
20140188221 Chung et al. Jul 2014 A1
20140194981 Menk et al. Jul 2014 A1
20140194983 Kovalsky et al. Jul 2014 A1
20140207231 Hacohen et al. Jul 2014 A1
20140214159 Vidlund Jul 2014 A1
20140222136 Geist et al. Aug 2014 A1
20140222142 Kovalsky et al. Aug 2014 A1
20140236287 Clague et al. Aug 2014 A1
20140236289 Alkhatib Aug 2014 A1
20140249622 Carmi et al. Sep 2014 A1
20140257461 Robinson et al. Sep 2014 A1
20140257467 Lane et al. Sep 2014 A1
20140257475 Gross et al. Sep 2014 A1
20140277358 Slazas Sep 2014 A1
20140277409 Börtlein et al. Sep 2014 A1
20140277411 Börtlein et al. Sep 2014 A1
20140277418 Miller Sep 2014 A1
20140277422 Ratz et al. Sep 2014 A1
20140277427 Ratz et al. Sep 2014 A1
20140296962 Cartledge et al. Oct 2014 A1
20140296969 Tegels et al. Oct 2014 A1
20140324164 Gross et al. Oct 2014 A1
20140336744 Tani et al. Nov 2014 A1
20140343670 Bakis et al. Nov 2014 A1
20140350662 Vaturi Nov 2014 A1
20140350670 Keranen Nov 2014 A1
20140358224 Tegels et al. Dec 2014 A1
20140379065 Johnson et al. Dec 2014 A1
20140379074 Spence et al. Dec 2014 A1
20140379076 Vidlund et al. Dec 2014 A1
20150018944 O'Connell et al. Jan 2015 A1
20150045881 Lim Feb 2015 A1
20150094802 Buchbinder et al. Apr 2015 A1
20150119970 Nakayama et al. Apr 2015 A1
20150127097 Neumann et al. May 2015 A1
20150142100 Morriss et al. May 2015 A1
20150142103 Vidlund May 2015 A1
20150157458 Thambar et al. Jun 2015 A1
20150173896 Richter et al. Jun 2015 A1
20150173897 Raanani et al. Jun 2015 A1
20150238313 Spence et al. Aug 2015 A1
20150245934 Lombardi et al. Sep 2015 A1
20150272730 Melnick et al. Oct 2015 A1
20150282964 Beard et al. Oct 2015 A1
20150320556 Levi et al. Nov 2015 A1
20150327994 Morriss et al. Nov 2015 A1
20150328000 Ratz et al. Nov 2015 A1
20150335429 Morriss et al. Nov 2015 A1
20150351903 Morriss et al. Dec 2015 A1
20150351904 Cooper et al. Dec 2015 A1
20150359629 Ganesan et al. Dec 2015 A1
20160030169 Shahriari Feb 2016 A1
20160030171 Quijano et al. Feb 2016 A1
20160106539 Buchbincier et al. Apr 2016 A1
20160113766 Ganesan et al. Apr 2016 A1
20160113768 Ganesan et al. Apr 2016 A1
20160125160 Heneghan et al. May 2016 A1
20160220367 Barrett Aug 2016 A1
20160228247 Maimon et al. Aug 2016 A1
20160242902 Morriss et al. Aug 2016 A1
20160270911 Ganesan et al. Sep 2016 A1
20160310268 Oba et al. Oct 2016 A1
20160317301 Quadri et al. Nov 2016 A1
20160317305 Pelled et al. Nov 2016 A1
20160324635 Vidlund et al. Nov 2016 A1
20160324640 Gifford, III et al. Nov 2016 A1
20160331526 Schweich, Jr. et al. Nov 2016 A1
20160331527 Vidlund et al. Nov 2016 A1
20160374801 Jimenez et al. Dec 2016 A1
20160374802 Levi et al. Dec 2016 A1
20170042678 Ganesan et al. Feb 2017 A1
20170056166 Ratz et al. Mar 2017 A1
20170056171 Cooper et al. Mar 2017 A1
20170128205 Tamir et al. May 2017 A1
20170135816 Lashinski et al. May 2017 A1
20170189174 Braido et al. Jul 2017 A1
20170196688 Christianson et al. Jul 2017 A1
20170196692 Kirk et al. Jul 2017 A1
20170209264 Chau et al. Jul 2017 A1
20170216026 Quill et al. Aug 2017 A1
20170231759 Geist et al. Aug 2017 A1
20170231760 Lane et al. Aug 2017 A1
20170333187 Marlton et al. Nov 2017 A1
20180021129 Peterson et al. Jan 2018 A1
20180049873 Manash et al. Feb 2018 A1
20180055628 Patel et al. Mar 2018 A1
20180055630 Patel et al. Mar 2018 A1
20180153689 Maimon et al. Jun 2018 A1
20180177594 Patel et al. Jun 2018 A1
20180206983 Noe et al. Jul 2018 A1
20180250126 O'connor et al. Sep 2018 A1
20180296336 Cooper et al. Oct 2018 A1
20180296341 Noe et al. Oct 2018 A1
20180344457 Gross et al. Dec 2018 A1
20180353294 Calomeni et al. Dec 2018 A1
20190053896 Adamek-bowers et al. Feb 2019 A1
20190060060 Chau et al. Feb 2019 A1
20190060068 Cope et al. Feb 2019 A1
20190060070 Groothuis et al. Feb 2019 A1
20190117391 Humair Apr 2019 A1
20190175339 Vidlund Jun 2019 A1
20190216602 Lozonschi Jul 2019 A1
20190350701 Adamek-bowers et al. Nov 2019 A1
20190388218 Vidlund et al. Dec 2019 A1
20190388220 Vidlund et al. Dec 2019 A1
Foreign Referenced Citations (60)
Number Date Country
1264582 Dec 2002 EP
1768630 Jul 2015 EP
9843557 Oct 1998 WO
9930647 Jun 1999 WO
0047139 Aug 2000 WO
0162189 Aug 2001 WO
0187190 Nov 2001 WO
2005107650 Nov 2005 WO
2006007401 Jan 2006 WO
2006054930 May 2006 WO
2006070372 Jul 2006 WO
2006089236 Aug 2006 WO
2007059252 May 2007 WO
2008013915 Jan 2008 WO
2008029296 Mar 2008 WO
2008070797 Jun 2008 WO
200103722 Aug 2008 WO
2009033469 Mar 2009 WO
2009053497 Apr 2009 WO
2009091509 Jul 2009 WO
2010006627 Jan 2010 WO
2010037141 Apr 2010 WO
2010057262 May 2010 WO
2010081033 Jul 2010 WO
2010121076 Oct 2010 WO
2011025972 Mar 2011 WO
2011069048 Jun 2011 WO
2011106137 Sep 2011 WO
2011111047 Sep 2011 WO
2011137531 Nov 2011 WO
2011143263 Nov 2011 WO
2012011108 Jan 2012 WO
2012024428 Feb 2012 WO
2012036740 Mar 2012 WO
2012048035 Apr 2012 WO
2012127309 Sep 2012 WO
2012177942 Dec 2012 WO
2013021374 Feb 2013 WO
2013021375 Feb 2013 WO
2013059747 Apr 2013 WO
2013072496 May 2013 WO
2013078497 Jun 2013 WO
2013128436 Sep 2013 WO
2013175468 Nov 2013 WO
2014022124 Feb 2014 WO
2014145338 Sep 2014 WO
2014164364 Oct 2014 WO
2014194178 Dec 2014 WO
2015173794 Nov 2015 WO
2016093877 Jun 2016 WO
2017223486 Dec 2017 WO
2018025260 Feb 2018 WO
2018029680 Feb 2018 WO
2018039631 Mar 2018 WO
2018106837 Jun 2018 WO
2018112429 Jun 2018 WO
2018118717 Jun 2018 WO
2018131042 Jul 2018 WO
2018131043 Jul 2018 WO
2019195860 Oct 2019 WO
Non-Patent Literature Citations (126)
Entry
An International Search Report and a Written Opinion both dated May 13, 2019, which issued during the prosecution of Applicant's PCT/IL2018/051350.
An International Search Report and a Written Opinion both dated Apr. 25, 2019, which issued during the prosecution of Applicant's PCT/IL2019/050142.
An International Search Report and a Written Opinion both dated Jan. 25, 2019, which issued during the prosecution of Applicant's PCT/IL2018/051122.
An International Search Report and a Written Opinion both dated Dec. 5, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050725.
An International Preliminary Report on Patentability dated Feb. 12, 2019, which issued during the prosecution of Applicant's PCT/IL2017/050873.
An International Preliminary Report on Patentability dated Feb. 5, 2019, which issued during the prosecution of Applicant's PCT/IL2017/050849.
An Office Action dated Mar. 25, 2019, which issued during the prosecution of European Patent Application No. 14710060.6.
An Office Action dated Oct. 25, 2018, which issued during the prosecution of U.S. Appl. No. 14/763,004.
An Office Action dated Mar. 4, 2019, which issued during the prosecution of U.S. Appl. No. 14/763,004.
An Office Action dated Jan. 9, 2019, which issued during the prosecution of U.S. Appl. No. 15/329,920.
An Office Action dated Jan. 30, 2019, which issued during the prosecution of U.S. Appl. No. 15/872,501.
An Office Action dated Feb. 5, 2019, which issued during the prosecution of U.S. Appl. No. 15/899,858.
An Office Action dated May 23, 2019, which issued during the prosecution of U.S. Appl. No. 15/668,659.
An Office Action dated May 1, 2019, which issued during the prosecution of U.S. Appl. No. 15/691,032.
International Search Report and Written Opinion dated Nov. 9, 2018, PCT/IL2018/050869.
Extended European Search Report dated Sep. 26, 2018; Appln. No. 18186764.7.
The First Chinese Office Action dated Nov. 5, 2018; Appln. No. 201680008328.5.
Invitation to pay additional fees dated Oct. 11, 2018; PCT/IL2018/050725.
USPTO NFOA dated Dec. 4, 2018 in connection with U.S. Appl. No. 16/045,059.
USPTO NOA mailed Sep. 25, 2018 in connection with U.S. Appl. No. 15/188,507.
Invitation to pay additional fees dated Jan. 2, 2018; PCT/L2017/050849.
USPTO Interview Summary dated Feb. 8, 2018 in connection with U.S. Appl. No. 15/213,791.
USPTO NFOA dated Jan. 5, 2018 in connection with U.S. Appl. No. 15/541,783.
USPTO NFOA dated Feb. 2, 2018 in connection with U.S. Appl. No. 15/329,920.
USPTO NFOA dated Feb. 7, 2018 in connection with U.S. Appl. No. 15/197,069.
USPTO NFOA dated Oct. 23, 2017 in connection with U.S. Appl. No. 14/763,004.
USPTO NFOA dated Dec. 7, 2017 in connection with U.S. Appl. No. 15/213,791.
Invitation to pay Additional Fees dated Sep. 29, 2017; PCT/IL2017/050873.
Extended European Search Report dated Jun. 29, 2017; Appln. 11809374.9.
Alexander S. Geha, et al; “Replacement of Degenerated Mital and Aortic Bioprostheses Without Explantation”, Ann. Thorac. Surg. Jun. 2001; 72:1509-1514.
Dominique Himbert, MD; “Mitral Regurgitation and Stenosis from Bioprosthesis and Annuloplasty Failure: Transcatheter approaches and outcomes”, 24 pages, Oct. 28, 2013.
J. Jansen, et al; “Detachable shape-memory sewing ring for heart valves”, Artificial Organs, 16:294-297 1992 (An Abstract).
Frank Langer MD, et al; “RING plus STRING: Papillary muscle repositioning as an adjunctive repair technique for ischemic mitral regurgitation”, J. Thorac Cardiovasc. Surg. 133:247-9, Jan. 2007.
Frank Langer, MD, et al: “RING+STRING: Successful Repair Technique for Ischemic Mitral Regurgitation With Severe Leaflet lathering”, Circulation 120[suppl 1]: S85-S91. Sep. 2009.
Righini presentation EuroPCR May 2015 (Saturn)-(downloaded from: https://www.pcronline.com/Cases-resourceimages/Resources/Course-videos-slides/2015/Cardiovascularinnovation-pipeline-Mitral-and-tricuspid-valve-interventions).
Saturn Project—a novel solution for transcatheter heart valve replacement specifically designed to address clinical therapeutic needs on mitral valve: Dec. 2016.
John G. Webb, et al; “Transcatheter Valve-in-Valve Implantation for Failed Bioprosthetic Heart Valves”, Circulation, Apr. 2010, 121: 1848-1857.
An Office Action dated Jun. 6, 2018, which issued during the prosecution of UK Patent Application No. 1720803.4.
An Office Action dated Jun. 18, 2018, which issued during the prosecution of UK Patent Application No. 1800399.6.
An International Search Report and a Written Opinion both dated Jun. 20, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050024.
USPTO AA dated Apr. 2, 2018 in connection with U.S. Appl. No. 14/763,004.
USPTO NFOA dated Apr. 20, 2018 in connection with U.S. Appl. No. 15/886,517.
USPTO NFOA dated Jun. 28, 2018 in connection with U.S. Appl. No. 29/635,658.
USPTO NFOA dated Jun. 28, 2018 in connection with U.S. Appl. No. 29/635,661.
USPTO NFOA dated Aug. 9, 2018 in connection with U.S. Appl. No. 15/899,858.
USPTO NFOA dated Aug. 9, 2018 in connection with U.S. Appl. No. 15/902,403.
USPTO NOA mailed Apr. 20, 2018 in connection with U.S. Appl. No. 15/878,206.
USPTO NFOA dated Jul. 26, 2018 in connection with U.S. Appl. No. 15/872,501.
USPTO RR dated May 4, 2018 in connection with U.S. Appl. No. 15/872,501.
An Office Action dated Nov. 1, 2019, which issued during the prosecution of U.S. Appl. No. 15/872,501.
An Office Action dated Jun. 25, 2019, which issued during the prosecution of U.S. Appl. No. 15/329,920.
An Office Action dated May 16, 2019, which issued during the prosecution of U.S. Appl. No. 15/433,547.
An Office Action dated Aug. 1, 2019, which issued during the prosecution of U.S. Appl. No. 15/668,559.
An Office Action dated Aug. 16, 2019, which issued during the prosecution of U.S. Appl. No. 15/668,659.
An Office Action dated Jun. 19, 2019, which issued during the prosecution of U.S. Appl. No. 15/682,789.
An Office Action dated Jun. 14, 2019, which issued during the prosecution of U.S. Appl. No. 15/703,385.
An Office Action dated Oct. 4, 2019, which issued during the prosecution of U.S. Appl. No. 16/183,140.
An Office Action dated Jun. 13, 2019, which issued during the prosecution of U.S. Appl. No. 16/388,038.
An Office Action dated Sep. 13, 2019, which issued during the prosecution of U.S. Appl. No. 16/460,313.
An Office Action dated Nov. 26, 2019, which issued during the prosecution of U.S. Appl. No. 16/532,945.
USPTO FOA dated Feb. 10, 2014 in connection with U.S. Appl. No. 13/033,852.
USPTO FOA dated Feb. 15, 2013 in connection with U.S. Appl. No. 12/840,463.
USPTO FOA dated May 23, 2014 in connection with U.S. Appl. No. 13/412,814.
USPTO FOA dated Jul. 18, 2013 in connection with U.S. Appl. No. 13/044,694.
USPTO FOA dated Jul. 23, 2013 in connection with U.S. Appl. No. 12/961,721.
USPTO NFOA dated Jan. 18, 2017 in connection with U.S. Appl. No. 14/626,267.
USPTO NFOA dated Jan. 21, 2016 in connection with U.S. Appl. No. 14/237,264.
USPTO NFOA dated Feb. 6, 2013 in connection with U.S. Appl. No. 13/412,814.
USPTO NFOA dated Feb. 7, 2017 in connection with U.S. Appl. No. 14/689,608.
USPTO NFOA dated May 29, 2012 in connection with U.S. Appl. No. 12/840,463.
USPTO NFOA dated Jun. 4, 2014 in connection with U.S. Appl. No. 12/840,463.
USPTO NFOA dated Jun. 17, 2014 in connection with U.S. Appl. No. 12/961,721.
USPTO NFOA dated Jul. 1, 2016 in connection with U.S. Appl. No. 14/161,921.
USPTO NFOA dated Jul. 2, 2014 in connection with U.S. Appl. No. 13/811,308.
USPTO NFOA dated Jul. 3, 2014 in connection with U.S. Appl. No. 13/033,852.
USPTO NFOA dated Aug. 2, 2013 in connection with U.S. Appl. No. 13/033,852.
USPTO NFOA dated Sep. 12, 2013 in connection with U.S. Appl. No. 13/412,814.
USPTO NFOA dated Sep. 19, 2014 in connection with U.S. Appl. No. 13/044,694.
USPTO NFOA dated Nov. 8, 2013 in connection with U.S. Appl. No. 12/840,463.
USPTO NFOA dated Nov. 23, 2012 in connection with U.S. Appl. No. 13/033,852.
USPTO NFOA dated Nov. 27, 2015 in connection with U.S. Appl. No. 14/626,267.
USPTO NFOA dated Nov. 28, 2012 in connection with U.S. Appl. No. 12/961,721.
USPTO NFOA dated Dec. 10, 2015 in connection with U.S. Appl. No. 14/237,258.
USPTO NFOA dated Dec. 31, 2012 in connection with U.S. Appl. No. 13/044,694.
USPTO NOA mailed Mar. 29, 2017 in connection with U.S. Appl. No. 14/161,921.
USPTO NOA mailed Aug. 15, 2014 in connection with U.S. Appl. No. 13/412,814.
USPTO RR dated Jan. 20, 2016 in connection with U.S. Appl. No. 14/161,921.
USPTO RR dated Feb. 3, 2014 in connection with U.S. Appl. No. 13/811,308.
USPTO RR dated Jul. 2, 2012 in connection with U.S. Appl. No. 13/033,852.
USPTO RR dated Aug. 13, 2012 in connection with U.S. Appl. No. 13/044,694.
USPTO RR dated Aug. 14, 2012 in connection with U.S. Appl. No. 12/961,721.
USPTO RR dated Sep. 26, 2016 in connection with U.S. Appl. No. 14/763,004.
Extended European Search Report dated Feb. 18, 2015; Appln. No. 12621522.5-1651/2739214 PCT/IL2012000293.
EPO Office Action dated Feb. 10, 2017; Appln. No. 12 821 522.5-1651.
UK Office Action dated Feb. 8, 2017; Appln. No. 1613219.3.
Invitation to Pay Additional Fees dated Jun. 12, 2014 PCT/IL2014/050087.
IPRP issued Dec. 2, 2013; PCT/IL2011/000582.
IPRP issued Sep. 11, 2012; PCT/IL2011/000231.
IPRP issued Feb. 11, 2014; PCT/IL2012/000292.
IPRP issued Feb. 11, 2014; PCT/IL2012/000293.
International Search Report and Written Opinion dated Oct. 13, 2011; PCT/IL11/000231.
International Search Report and Written Opinion dated Dec. 5, 2011; PCT/IL11/00582.
International Search Report and Written Opinion dated Feb. 6, 2013; PCT/IL12/00293.
International Search Report and Written Opinion dated Mar. 17, 2014: PCT/IL13/50937.
International Search Report and Written Opinion dated Feb. 6, 2013; PCT/IL12/00292.
International Search Report and Written Opinion dated Apr. 9, 2014; PCT/IL2014/050087.
International Search Report and Written Opinion dated Oct. 27, 2015; PCT/IL2015/050792.
International Search Report and Written Opinion dated May 30, 2016; PCT/IL2016/050125.
U.S. Appl. No. 61/283,819.
U.S. Appl. No. 61/492,449.
U.S. Appl. No. 61/515,372.
U.S. Appl. No. 61/525,281.
U.S. Appl. No. 61/537,276.
U.S. Appl. No. 61/555,160.
U.S. Appl. No. 61/588,892.
U.S. Appl. No. 61/756,034.
U.S. Appl. No. 61/756,049.
An Office Action dated Jan. 6, 2020 which issued during the prosecution of U.S. Appl. No. 16/660,231.
An Office Action dated Dec. 31, 2019, which issued during the prosecution of U.S. Appl. No. 16/183,140.
An Office Action dated Jan. 14, 2020, which issued during the prosecution of U.S. Appl. No. 16/284,331.
Notice of Allowance dated Januar 13, 2020, which issued during the prosecution of U.S. Appl. No. 15/956,956.
European Search Report dated Mar. 5, 2020 which issued during the prosecution of Applicant's European App No. 17752184.6.
European Search Report dated Mar. 4, 2020 which issued during the prosecution of Applicant's Euroean App No. 16706913.7.
Notice of Allowance dated Mar. 12, 2020, which issued during the prosecution of U.S. Appl. No. 16/460,313.
An Office Action dated Feb. 6, 2020, which issued during the prosecution of U.S. Appl. No. 15/668,659.
An Office Action dated Jan. 3, 2020, which issued during the prosecution of U.S. Appl. No. 16/678,355.
Related Publications (1)
Number Date Country
20170252159 A1 Sep 2017 US
Provisional Applications (2)
Number Date Country
61756034 Jan 2013 US
61756049 Jan 2013 US
Continuations (1)
Number Date Country
Parent 14161921 Jan 2014 US
Child 15600190 US